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ABSTRACT OF DISSERTATION
Lung cancer is a leading cause of cancer-related mortality irrespective of gender.
The Sulfiredoxin (Srx) and Peroxiredoxin (Prx) are a group of thiol-based
antioxidant proteins that plays an essential role in non-small cell lung cancer.
Understanding the molecular characteristics of the Srx-Prx interaction may help
design the strategies for future development of therapeutic tools. Based on
existing literature and preliminary data from our lab, we hypothesized that the Srx
plays a critical role in lung carcinogenesis and targeting the Srx-Prx axis or Srx
alone may facilitate future development of targeted therapeutics for prevention
and treatment of lung cancer. First, we demonstrated the oncogenic role of Srx in
urethane-induced lung carcinogenesis in genetically modified FVB mice. The
Srx-null mice showed resistance to urethane-induced lung cancer. Second, we
demonstrated the Srx and Prx sites important for Srx-Prx interaction. The
orientation of this arm is demonstrated to cause some steric hindrance for the
Srx-Prx interaction as it substantially reduces the rate of association between Srx
and Prx. Finally, we carried out virtual screening to identify molecules that can
successfully target Srx-Prx interaction. Multiple in-silico filters were used to
minimize the number of chemicals to be tested. We identified ISO1 as an
inhibitor of the Srx-Prx interaction. KD value for Srx-ISO1 interaction is calculated
to be 42 nM. Together, these data helps to identify an inhibitor (ISO1) of the SrxPrx interaction that can be further pursued to be developed as a
chemotherapeutic tool.
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CHAPTER 1: INTRODUCTION
1.1 Background
Redox signaling is signaling involving oxidation-reduction cycles of molecules
leading to cell signal transduction. Redox signaling is an essential component of
cellular processes involved in the maintenance of physiological homeostasis. It is
an integral part of eukaryotic as well as prokaryotic cell signaling. The
physiological activities regulated by redox signaling include (but are not limited
to) growth factor signaling such as epidermal growth factor (EGF) [1] and insulinlike growth factor [2] as well as important energy metabolism and hormonal
signaling [3]. Reactive oxygen/nitrogen species (ROS/RNS) are highly reactive
oxygen/nitrogen containing species. ROS/RNS have a very short half-life, partly
due to their highly reactive nature and the presence of antioxidants in host
organisms. Any imbalance in production and utilization of ROS/RNS leads to
abnormal accumulation of these particles. This abnormal accumulation of highly
reactive molecules is known as oxidative stress. Oxidative stress contributes to
multiple disorders in humans, including diabetes, Alzheimer’s disease,
Parkinson’s disease, hepatic diseases, and various types of cancer [4, 5].
Antioxidants are molecules that are preferentially oxidized under oxidative stress
conditions. They can be internal housekeeping molecules (expressed in
intracellular or extracellular compartments of animal tissue) or external molecules
(part of daily diet or supplements). Every organism expresses many antioxidant
molecules at intracellular and extracellular sites to protect it from oxidative
damages. Thiol-based antioxidants are major internal housekeeping antioxidant
1

molecules that act as redox switches to maintain physiological homeostasis [6].
Peroxiredoxins (Prxs) and sulfiredoxin (Srx) are part of the thiol-based
antioxidant system.

1.1.1 Peroxiredoxin
Prx is a class of thiol-based peroxidases ubiquitously found in prokaryotes as
well as eukaryotes. Prx was first discovered about 27 years ago in yeast [7].
These proteins initially had multiple names, for example, protector protein, thiolspecific antioxidants, thioredoxin-linked thiol peroxidase and thioredoxin
peroxidase. Finally, they were classified and widely accepted as peroxiredoxin
[7-12]. There are six different isoforms of Prxs expressed in humans (i.e., Prx1-6)
[13]. These Prx are involved in the regulation of cell proliferation, apoptosis,
embryonic development, lipid metabolism, immune response, and other
functions. [14]. All human Prx have one enzymatic cysteine called peroxidatic
cysteine (CP) on their N-terminus. Five out of six human Prxs also have another
cysteine called resolving cysteine (CR) on their C-terminus. Classification of Prx
is largely based on the presence and the behavior of CR. Human Prx are
classified into three groups: (i) typical 2-Cys Prx (i.e. Prx1-4), (ii) atypical 2-Cys
Prx (i.e. Prx5), and (iii) 1-Cys Prx (i.e. Prx6) [15]. A few publications reported the
N-terminus as a reference for location of CP and CR. However, distance between
CP and CR is not the same among different typical 2-Cys Prxs. From the
comparison of typical 2-Cys Prxs, we found that the C-terminal of Prxs can be a
better reference for CP and CR as their distance from the C-terminal end is
approximately fixed across all typical 2-Cys Prx. For example, the CP is at a
2

distance of 148-149 amino acids from the C-terminal end whereas the CR is at a
distance of 27-28 amino acids from the C-terminal end. The Prx family of proteins
reduces hydrogen peroxide (H2O2), alkyl hydroperoxides and peroxynitrite into
water and other harmless metabolites. In this reaction, the thiol group of CP is
oxidized to sulfenic acid. The cysteine-sulfenic acid group can be enzymatically
reduced back by the glutaredoxin or thioredoxin (Trx)-thioredoxin reductase
system [16, 17]. The pKa of most biological cysteines is in the range of 8-9 if it is
not stabilized by other molecular factors, while the pKa of CP falls in a lower range
of 5-6 due to stabilization by the conserved arginine and threonine residues in
neighboring positions [18]. There is no evidence of stabilization of CR by any
intramolecular factors. Therefore, the pKa of CR should remain in the same range
as other non-stabilized biological cysteines (i.e., 8-9). The difference in pKa
values makes CR resistant to oxidation compared to CP. The rate constant (k) of
Prx-thiol oxidation is higher than most other thiol-based antioxidant proteins. It is
the main reason why Prx are 105-107 times more efficient antioxidants compared
to other thiol-based antioxidants such as glutathione, Trx, glyceraldehyde-3phosphate dehydrogenase (GAPDH), protein-tyrosine phosphatase 1B (PTP1B),
etc. [19]. Higher rate constant and lower pKa are indicators of the Prx’s ability to
reduce ROS that are present even in minute amounts. If the oxidative stress level
is high and/or the amount of Prx is low, the CP can become over-oxidized to
sulfinic (-SOOH) or sulfonic acid (-SOOOH) forms, leading to the loss of
antioxidant activity [20]. Figure 1-1 shows this reaction along with Srx mechanism
of action.
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Figure 1-1: Sulfiredoxin reduces over-oxidized peroxiredoxin and acts as a switch to regulate antioxidant vs
chaperone function of peroxiredoxin : Figure shows the relative location of CP in Prx monomer and its role in the
reduction of ROS. It also shows how the Srx forms phosphoryl esters and thiosulfinate intermediate finally leading to
reduction of Prx Cys-sulfinic (-SOOH) form to Cys-sulfenic (-SOH) acid form.

Over-oxidation of Prxs is detectable in almost all eukaryotes and a few
prokaryotes such as cyanobacteria [21]. Earlier literature indicated that the
hyperoxidation of Prxs is a unique property of eukaryotic Prxs. However, the
latest reports present evidence of this phenomenon in prokaryotes too [21].
Hyperoxidation and loss of antioxidant function is not a disadvantage for the host.
The hyperoxidation of Prxs adds an additional molecular chaperone function to a
few members of this class [22]. However, the molecular basis behind gain of
chaperone function is yet to be identified. Further research is required to identify
proteins whose folding is assisted by Prx. The chaperone function of Prx was
considered a unique property of eukaryotic Prx until similar activity was detected
in prokaryotes such as Helicobacter pylori [23].

1.1.2 Sulfiredoxin
Experts long wondered about the existence of enzymes having the potential to
reduce over-oxidized Prxs until Srx was identified in Saccharomyces cerevisiae
[24] and was later found to be conserved in higher eukaryotes and a few
prokaryotes (e.g. cyanobacteria). Srx plays a role in the reduction of overoxidized Prxs and hence acts as a regulator of oligomerization of these Prxs.
Rate constants from two independent studies indicate that the reduction of
oxidized Prxs by Trx (rate constant 106 M-1s-1) is much faster than the rate of
reduction of over-oxidized Prxs by Srx (rate constant approximately 2 M-1s-1) [25,
26]. Therefore, reduction of over-oxidized Prx by Srx can be considered a ratelimiting step in the reduction of over-oxidized Prxs.
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The closest prokaryotic counterpart of Srx is a functionally unrelated protein
called ‘ParB’ in bacteria, which carries out the function of chromosome
partitioning [27]. The ‘Oncogenic suppressive activity’ or ‘Osa’ protein is probably
a connecting link between ParB and Srx. Osa contains both the DNAse domain
[18] of ParB and the ATPase domain of Srx [28]. Srx requires ATPase domain
for ATP hydrolysis required for Prx reduction. The ‘ParB’ is a chromosome
partitioning protein that requires a DNAse domain for its function. In normal
human tissues, Srx is present in kidney, lungs, and pancreas [29]. Srx is mainly a
cytosolic protein that can translocate into mitochondria under oxidative stress
conditions [30]. Recent research suggests that mitochondrial Srx level follows
circadian rhythm [31]. In this manner, Prx3 along with Srx plays an important role
in the management of mitochondrial redox balance.
The Srx-Prx axis can be explored as a therapeutic target as well as a therapeutic
tool depending on its role in a particular pathological condition. For example,
individual Prx can be considered as a good therapeutic targets in lung cancer
[32], glioblastoma [33], colorectal cancer [34], and prostate cancer [35], where
they protect tumor cells. It is important to evaluate the risk-benefit ratio of
targeting individual members of the Srx-Prx axis as they also have a protective
role in normal (non-tumor) tissue. Srx null mice have a normal phenotype under
laboratory conditions [34]. Prx3 knockout mice are born and mature normally
[36]. Prx4 knockout mice have mild prostate atrophy [37]. Prx1 and Prx2
knockout mice are reported to have some issue with erythropoiesis [38, 39] but
they are otherwise normal. Hence, the majority of proteins in the Srx-Prx axis can
6

be knocked-out without any life-threatening issue under non-stress conditions.
Considering the risk associated with cancer, it is worth exploring targets that can
prolong the lives of patients by a few extra years. Hence, the benefits associated
with targeting Srx or individual Prx outweigh the associated risk; therefore, the
Srx-Prx system can be considered as therapeutic target in cancer. On the other
hand, individual Prxs can be explored as a therapeutic or diagnostic tool in
Parkinson’s disease, Alzheimer’s disease, and diabetic complications [40-44].
These differential properties of individual components of the Srx-Prx system draw
our attention to differences in molecular properties of individual Prx that gives
them the ability to play such diverse roles. An improved understanding of these
molecular differences will help us in therapeutic intervention of the Srx-Prx
system.

1.1.3 Enzymatic roles of Srx
Human Srx has a length of 137 amino acids [45]. Srx is present in mammals,
birds, and many (not all) other eukaryotic organisms [46]. It is an exclusive
enzyme that acts as an antioxidant to reduce the sulfinic acid form of typical 2Cys Prxs [47]. Biteau and colleagues identified how adenosine triphosphate
(ATP)-bound yeast Srx in the presence of Mg2+ approaches the over-oxidized
Prx1, phosphorylates it, and forms thiosulfinate intermediate, which can be
further reduced by other thiol-reducing enzymes [24]. Yeast Srx has cysteine at
two locations in its primary sequence; the first cysteine (Cys48) helps the
enzymatic cysteine (Cys84) by recycling the thiosulfinate intermediate [48].
However, human Srx has only one cysteine, i.e. Cys99 (a homologue of Cys84 of
7

yeast). Therefore, it needs an external source of thiol, such as Trx or glutathione,
to reduce the thiosulfinate intermediate [48, 49]. The evolution of an ATP
consuming process to reactivate Prxs after deactivation of their peroxidase
function by H2O2 provides a unique advantage to the host organism. The H2O2
and Srx act as an On-Off switch for the chaperone and peroxidase functions of
various Prx. The excess of H2O2 enhances the chaperone function and reduces
the peroxidase function of Prxs, whereas an excess of Srx reverses this process
[50]. Figure 1-1 depicts the mechanism by which Srx performs the
aforementioned antioxidant function. The Prx structure in this figure is designed
to give a rough idea about the positions of individual cysteine in a typical 2-Cys
Prx. The C-terminal CR is shown in the C-terminal arm and the other cysteine in
Prx indicates the N-terminal CP.
Another important action of Srx involves the deglutathionylation of several
substrates in eukaryotes [45]. Most of the Prx-independent and a few Prxdependent functions of Srx are mediated by this mechanism. Figure 1-2 depicts
the role of Srx in the deglutathionylation process. Srx can regulate the chaperone
function of Prx1 by controlling its levels of glutathionylation. The glutathionylation
of Cys83 of Prx1 favors formation of dimer over decamer, resulting in the loss of
chaperone activity [51]. Although it is a general consensus that Prx-reducing
activity of Srx is more important than its deglutathionylation function, more
mechanistic studies are required to assess the individual contribution of Prx
reduction and deglutathionylation processes in regulating the chaperone function
of Prx1 or other typical 2-Cys Prxs.
8
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Figure 1-2: Mechanism of the deglutathionylation function of sulfiredoxin : Figure shows how glutathione assists
sulfiredoxin in carrying out this function.

There is no evidence of tissue specific predominance of one Srx function over
the other. However, there is a great scope for exploration of Srx
deglutathionylation function. The lack of extensive biochemical studies in this
field may be a possible reason behind the difficulty in ranking the importance of
antioxidant vs. deglutathionylation functions of Srx. Unlike the antioxidant
function of Srx, which is exclusive to Prxs, the deglutathionylation carried out by
Srx does not seem to be limited to Prxs. S100A4, actin and PTP1B are examples
of substrates other than Prx whose glutathionylation levels can be regulated by
Srx [22, 52]. There may be other intracellular targets of Srx that can be
deglutathionylated by Srx. Identification of those substrates may help to identify
different mechanisms of Srx signaling.

1.1.4 Molecular characteristics of the Srx-Prx interaction
The Cys99 of human Srx is not involved in Srx-Prx binding but it is directly
involved in the antioxidant and deglutathionylation functions of Srx [47, 50, 53].
Amino acids adjacent to Cys99 (i.e., Gly97, Gly98, His100, and Arg101) are
considered to play a supportive role for the enzymatic activity of Srx [54]. Pro52,
Leu82, Phe96, Val118, Val127, and Tyr128 are amino acids that form a hydrophobic
pocket in Srx that acts as the interface for Srx-Prx interaction [54, 55]. The
hydrophobic pocket formed by the active site of Srx forms a depression that
wraps around the slightly protruding active site of Prx [54]. It acts as a lock and
key model of Srx-Prx interaction.
The Prx family of proteins is one of the most abundant and most efficacious
antioxidants in the human body. The enzymatic cysteine of Prx is called
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peroxidatic cysteine (CP). A few Prx isoforms also contain a cysteine called CR.
Classification of Prx is based mainly on the presence and behavior of CR in
different Prx-isoforms [15]. Individual Prxs also contain cysteines other than
peroxidatic and CR, which may play some regulatory role in these Prx. For
example, Cys83 of Prx1 mediates the formation of a decameric complex of Prx1
that differentiates the functions of Prx1 from Prx2 [56]. Despite sharing 78%
sequence similarity with other typical 2-Cys Prx, one cysteine of Prx1 (Cys83)
plays an especially important role as it is a highly efficient chaperone compared
to other Prx [56]. One report indicates that Cys83-Cys83 disulfide bond formation
is not essential for rat Prx1, in particular, as it forms a decameric structure
through

hydrophobic

interactions

and

van

der

Waals

bonds

[57].

Glutathionylation of Cys83 has been reported to negatively affect the chaperone
function of Prx1 [51]. However, the way the glutathionylation impacts the
chaperone activity of other typical 2-Cys Prxs remains to be understood.
The number of amino acids between the peroxidatic and CR is critical for the
formation of the Prx dimer. All human typical 2-Cys Prx have 121 amino acids
between the CP and CR. This 121 amino acid distance imparts the ability to form
an intermolecular disulfide bond between the CP of one typical 2-Cys Prx
monomer and the CR of another monomer and vicenegativersa. The bond results
in the formation of a homodimer of Prx in which the two Prx monomers are
oriented in an antiparallel manner. Under reduced state, these typical 2-Cys Prx
are still present in the form of a homodimer but the process involves only noncovalent interaction [58]. In atypical 2-Cys Prxs, there is a 104 amino acid
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distance between CP and CR [47]. This distance helps the Prx5 form an
intramolecular disulfide bond. The distance of CP and CR from the GGLG and YF
motif is another highly conserved feature of typical 2-Cys Prxs. The GGLG motif
is located between the CP and CR, 42 amino acids downstream of the CP. The YF
motif is localized between the CR and the N-terminus (i.e., 20 amino acids
downstream of CR). GGLG and YF motifs bestow these Prx with the unique
ability to become over-oxidized by H2O2 [59]. The YF motif interacts with the
GGLG motif, which hinders interaction between the CP of oxidized Prx and the CR
of the other monomer. This allows the second H2O2 molecule to react with the CP
of the first Prx monomer in a timely manner, resulting in the formation of overoxidized Prx [60]. In the absence of the GGLG and YF motifs, Prx will not
become over-oxidized, thus they are important for the chaperone function of Prxs
[59]. The GGLG and YF motifs were also identified in prokaryotic Prx [21]. The
chaperone function is gained by the formation of higher molecular weight
complexes that look like a stack of rings in transmission electron microscopy and
X-ray crystallography studies [61]. In some species, hyperoxidation of the CP is
not required for the gain of chaperone function, as their Prx can form a highmolecular weight structure in the absence of hyperoxidation [62]. However,
human Prxs have been known to gain chaperone function only after the CP is
over-oxidized. Susceptibility to hyperoxidation varies among the typical 2-Cys
Prxs. For example, Prx3 is considered more resistant to hyperoxidation than
other isoforms [63]. The conservation of amino acids around the CP probably
indicates their importance for the enzymatic activity or a particular behavior of a
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Prx isoform. For example, most Prx have a proline and a threonine (occasionally
serine) before the CP, forming a PXXXTXXC motif. This may be important for the
enzymatic activity of Prxs [64]. In human typical 2-Cys Prx, amino acids around
the CP (i.e. PLDFTFVCPTEI motif) and the CR (i.e. HGEVCPAXW motif) are
highly conserved [65]. This conserved sequence of amino acids around CP and
CR may indicate their importance for Prx function [66]. However, the significance
of these amino acids has not been experimentally proved yet and may be of
interest for further studies. Although all typical 2-Cys Prx are generally
considered substrates of Srx, the affinity of Srx to individual Prx is not the same
[32]. Srx has the highest affinity for Prx4 among all the typical 2-Cys Prxs [32].
However, the way this high affinity of interaction affects the kinetics of Prx4
reduction compared to other Prx still needs to be studied. Members of the Prx
family may have different subcellular localizations, and their abundance in
different tissues also varies. The interaction between Srx and different isoforms
of Prx is thus also affected by their subcellular localization. For example, the SrxPrx3 interaction becomes significant only under higher oxidative stress
conditions. At higher oxidative stress, the mitochondrial wall gets damaged.
Hence, Srx may translocate from cytosol to mitochondria through those damaged
mitochondrial walls [30]. At lower oxidative stress conditions, the Srx-Prx3
interaction is not noticeable. An alternative explanation of this phenomenon is
proposed in the literature: Prx3 can be over-oxidized only at higher oxidative
stress levels due to its high resistance to over-oxidation [63]. There may be some
molecular characteristics of reduced Prx3 that does not allow its interaction with
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Srx. Hence, the molecular rearrangement during over-oxidation of Prx3 becomes
necessary for facilitation of Srx-Prx3 interaction. However, more mechanistic
studies are required to clarify whether this is the case. All these molecular factors
affect signaling of the Srx-Prx axis. Differential affinity of Srx for individual Prx as
well as molecular characteristics of individual Prx allows them to regulate a wide
range of cell signaling, which I will discuss in detail in the next few sections.

1.1.5 The role of the Srx-Prx axis in cell-signaling and carcinogenesis
The main function of the Srx-Prx system is to protect host cells from oxidative
damages. This property of the Srx-Prx system becomes harmful to the host
organism when it starts protecting the survival of tumor cells. As per the data
from Oncomine (an online microarray database) [67] and other published
literature, the Srx-Prx system is altered in multiple types of cancer. Table 1-1
summarizes different types of cancer in which expression of individual members
of the Srx-Prx system is altered. The information in Table 1-1 indicates changes
in mRNA expression. Up-regulation indicates more than a 1.5 fold increase in
mRNA levels whereas down-regulation indicates more than a 1.5 folds decrease
in mRNA levels. Apart from mRNA, alterations at the protein level are also
reported for multiple tumor types. Information about expression changes at
places other than those shown in Table 1-1 are mainly based on studies of their
protein levels. The correlation between patient survival and protein expression
changes has not been studied. From published data, the Srx-Prx system
predominantly functions as an activator or enhancer of oncogenic signaling to
promote cancer development.
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Table 1-1: Expression pattern of the Srx-Prx system in different cancer types as evident from microarray
data available at Oncomine: Up-regulation is classified as more than a 1.5 fold increase in expression compared
to normal non-tumor cells; Down-regulation is classified as more than a 1.5 fold decrease in expression compared
to normal non-tumor cells. Data summarized here can be confirmed by other independent studies
Protein
Srx

Up-Regulation
Breast cancer, Colorectal cancer, Lung cancer,
Prostate cancer, Skin cancer
Bladder cancer, Colorectal cancer, Gastric cancer,

Prx1

Leukemia, Liver Cancer, Lymphoma, Breast cancer,
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Pancreatic cancer, Sarcoma

Prx2

Prx3

Colorectal cancer, Lung cancer, Lymphoma, Myeloma,
Ovarian cancer

Down-Regulation
Esophageal Cancer

Esophageal Cancer, Head & Neck cancer,
Myeloma
Brain & Central Nervous System (CNS) cancer,
Esophageal cancer, Head & Neck cancer, Kidney
cancer, Leukemia, Pancreatic cancer, Sarcoma

Gastric cancer, Head & Neck cancer, Lymphoma,

Bladder cancer, Brain & CNS cancer, Kidney

Prostate Cancer

cancer, Leukemia, Pancreatic cancer

Bladder cancer, Brain & CNS cancer, Breast cancer,
Prx4

Cervical cancer, Colorectal cancer, Head & Neck
cancer, Kidney cancer, Lung cancer, Lymphoma,
Melanoma, Prostate Cancer, Sarcoma

Leukemia, Liver cancer, Pancreatic cancer

A few reports have also indicated a tumor suppressor function of the Prx family.
Hence, Prx may function as a double-edged sword in tumorigenesis. The exact
role of the individual components of the Srx-Prx system in cancer can be
complicated, and should be considered in the context of specific cancer and cell
types.
1.1.5.1 Srx in cell-signal transduction and tumorigenesis

The expression of Srx is regulated by factors at both the transcriptional and
translational levels. Redox signaling is the major component that activates Srx
expression. Figure 1-3 summarizes how the expression of Srx is regulated by
redox signaling. Activation of transcription factors, such as nuclear factor
erythroid 2-related factor 2 (Nrf2), induces Srx expression [68]. Activator protein1 (AP-1) also up-regulates Srx expression [69]. c-Jun is a component of the AP-1
complex and its activation stimulates Srx expression. TAM67 is an N-terminal
deletion mutant of c-Jun that acts as a c-Jun antagonist. Therefore, TAM67
negatively regulates Srx expression by inhibiting the AP-1 complex [70]. Multiple
intracellular and extracellular factors such as nitric oxide, cigarette smoke, dietary
derived electrophiles, and tumor promoters like 12-O-tetradecanoylphorbol-13acetate (TPA) lead to the activation of Nrf2 or AP-1 and have the potential to
stimulate the expression of Srx [70, 71]. In mouse macrophages, treatment with
lipopolysaccharide strongly induces Srx expression in an Nrf2 and AP1
dependent

manner

[72].

Besides

these

transcriptional

regulations,

Srx

expression is negatively regulated at the translational level by cAMP-PKA (cyclic
AMP-protein kinase A) through the elF2 kinase Gcn2 [73].
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Figure 1-3: Oxidative stress stimulates sulfiredoxin expression by activating AP-1 and Nrf2 activity: AP-1 and Nrf2
transcriptionally regulates the sulfiredoxin expression.

Srx is over-expressed in a variety of cancers and it may promote carcinogenesis in a
Prx-dependent or independent manner [32, 52]. It promotes tumor progression in lung
cancer by enhancing intracellular phosphokinase signaling such as mitogen-activated
protein kinase (MAPK) and AP-1/MMP9 (matrix metalloproteinase 9) signaling in a
Prx4-dependent manner [32].
Srx may also enhance cell migration in lung cancer in a Prx-independent manner by
interacting with S100A4 (a calcium binding protein) and non-muscle myosin IIA [52].
Aberrant expression of Srx in lung squamous cell carcinoma, lung adenocarcinoma, and
pancreatic cancer is correlated with poor survival in patients [74-76]. Srx is also overexpressed in renal cell carcinoma where it is proposed to be a good target for antibody
to induce tumor cell death [77]. Srx expression is stimulated by TPA via MAPK/JNK (cJun N-terminal kinase) pathway in skin carcinogenesis and Srx depletion at least
partially protects mice against DMBA (7,12-dimethylbenz[a]anthracene) / TPA-induced
skin carcinogenesis [78]. Srx is also necessary for colon carcinogenesis as it is highly
over-expressed in colon tumor tissue compared to normal human colon, and Srx null
mice are highly resistant to azoxymethane/dextran sulfate sodium-induced colon
carcinogenesis [34]. Although the importance of Srx in various tumor types is well
established, research is needed to understand the mechanism by which Srx plays a role
in tumor progression and metastasis. Considering lung cancer as an example, the
antioxidant and deglutathionylation activities of Srx may work in tandem to enhance the
chances of tumor promotion and metastasis [32, 52]. However, more studies are
required before we can rank their individual contributions toward cancer. Unraveling the
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mechanistic details of Srx signaling will further help us design better approaches to
target tumors in which Srx plays an essential role.
1.1.5.2 Prx1 in cell-signal transduction and tumorigenesis

Prx1 is mainly localized in the cytoplasm and can translocate to the nucleus [79]. The
expression of Prx1 is regulated at both transcriptional and post-transcriptional levels. At
the transcriptional level, Nrf2 directly activates its expression [80]. Focal adhesion
kinase is also reported to be involved in transcriptional regulation of Prx1 [81]. In one
study, Prx1 null mice were shown to be prone to spontaneous tumor development [38],
suggesting that Prx1 may function as a tumor suppressor. However, Prx1 null mice
developed in another lab were normal and free of tumor development [82]. The tumor
suppressor function of Prx1 may be mediated by its regulation of PTEN (phosphatase
and tensin homolog) levels as indicated in a mouse breast cancer model [83]. Also,
PTEN null mouse embryonic fibroblasts are resistant to ROS-mediated induction of
Prx1/Prx2 expression [84]. Prx1 may also be required for ROS-mediated activation of
the K-Ras/ERK pathway that contributes to lung tumorigenesis [85]. Moreover, Prx1
along with Prx4 plays an essential role in the regulation of c-Jun and AP-1 mediated
promoter activity in lung cancer cells [86]. Activation of Prx1 by histone deacetylase
inhibitor (FK228), results in induction of apoptosis in esophageal tumor cells [87].
Furthermore, Prx1 helps reactivate DEP-1 (a protein tyrosine phosphatase that
functions as tumor suppressor) by reducing the levels of ROS [88]. These mechanisms
are a few examples of how Prx1 functions as a tumor suppressor.
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On the other hand, there are many reports indicating that Prx1 has an essential prooncogenic role in cancer. For example, Prx1 promotes vascular endothelial growth
factor expression in a toll-like receptor 4-dependent manner. This effect of Prx1
enhances angiogenesis and results in an environment favorable for tumor cell
proliferation and promotes tumor progression in prostate cancer [89, 90]. Prx1 is overexpressed in esophageal cancer cells and has an auto-immunogenic activity [91]. Prx1
protein is also found aberrantly increased in early stage endometrial cancer where its
functional significance is yet to be established [92]. Prx1 induces TRAIL (tumor necrosis
factor–related apoptosis-inducing ligand) resistance by suppressing the redoxdependent activation of caspase [93]. TRAIL is a biological agent that induces apoptosis
of cancer cells and is considered a promising anticancer agent [94]. Down-regulation of
Prx1 (using RNA interference or chemical agents like dioscin) results in induction of
apoptosis in tumor cells [95, 96]. Also, in A549 lung adenocarcinoma cells, Prx1
enhances the transforming growth factor (TGF)-β1 induced epithelial-mesenchymal
transition (EMT) by stimulating the expression of snail and slug—two transcription
factors that inhibit E-cadherin expression [97]. For this function, the Cys51 (CP) of Prx1 is
essential, as replacement of Cys51 by Ser nullifies this effect [97]. A study using murine
hepatocytes as well as human esophageal and lung cancer cell lines reports that TGFβ1 enhances ROS production by up-regulating the levels of ferritin heavy chain and
intracellular labile iron pool [98]. It can be inferred from these studies that ROS
produced by TGF-β1 signaling probably oxidizes the CP of Prx1 and this oxidation is
essential for the role of Prx1 in EMT. Therefore, higher levels of ROS may promote the
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progress of EMT. Whether and how the hyperoxidation of Prx1 and its molecular
chaperone activity are involved in the process of EMT is largely unknown. Figure 1-4
depicts how Prx can perform both tumor suppressor and oncogenic functions. The
factors that determine the dominance of one role over another are yet to be identified.
Possibly, Prx1 functions as a tumor suppressor before transformation, but after
transformation it promotes tumor cell proliferation by protecting against ROS-induced
cell death. Other possible explanations may be related to the single nucleotide
polymorphism or allelic variants of Prx1, but these factors need further investigation.
1.1.5.3 Prx2 in cell-signal transduction and tumorigenesis

Prx2 is the second member of the typical 2-Cys Prx. It is mainly present in cytosol [79]
and is one of the most efficient H2O2 scavengers in cells compared to the majority of
other antioxidants [99]. In red blood cells, the oxidation-reduction cycle of Prx2
correlates with the circadian rhythm resulting in circadian rhythm dependent
oligomerization of Prx2 [100]. This oscillation in levels of over-oxidized Prx2 is not
controlled at the transcriptional level since red blood cells do not have a nucleus [100]. It
is also not likely controlled by Srx, as the oscillations exist in Srx null mice [101]. Rather,
it is controlled by hemoglobin autoxidation and 20S proteasome in red blood cells that
are in turn regulated by circadian rhythm [101]. Extensive methylation of CpG islands in
the promoter region of the Prdx2 gene is one of the mechanisms to control Prx2
expression in melanoma [102]. Prx2 expression is also regulated by transcription factor
Hand1/Hand2 [103].
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Figure 1-4: Peroxiredoxin may act as a tumor-suppressor or oncogene depending on the tumor type.

In mouse embryonic fibroblasts, Prx2 is induced by ROS in a PTEN dependent
manner [84]. As mentioned earlier, PTEN activation is regulated by Prx1;
therefore, it can be assumed that Prx1 may have potential to affect Prx2
expression too. Prx2 is down-regulated in a few cancers where Prx1 is upregulated, but the exact mechanism behind the differential expression is not yet
known [104, 105]. Whether or not PTEN is responsible for this relationship
between Prx1 and Prx2 expression in those tissues remains a question.
Nitrosylation of Tyr193 in the YF motif of Prx2 is an important post-translational
modification that plays a critical role in regulation of disulfide bond formation
under oxidative stress conditions [106]. Glutathionylation is another posttranslational modification of Prx2 that may affect its localization to the
extracellular compartment [107]. Extracellular Prx2 is glutathionylated under
oxidative stress conditions and the glutathionylated form induces TNFα
production, leading to oxidative stress dependent inflammatory reaction [107]. In
this manner, Prx2 plays a role in cytokine mediated inflammation. Serum levels
of Prx2 in colorectal cancer are correlated with survival of patients [108]. In
human papillomavirus related cervical cancer, increased expression of Prx2 is
proposed to mediate carcinogenesis in cervical tissue [109, 110]. However, more
studies are required to establish whether alteration of Prx2 is a cause or effect of
carcinogenesis. Prx2 is the main factor determining the metabolic stress and
oxidative stress response of breast cancer cells metastasized to lung [111]. It
also regulates the activation of transcription factor STAT3 by transferring the
oxidative equivalents to the latter, resulting in generation of a disulfide-linked
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inactive STAT3 oligomer [99]. Prx2 reduces the chances of metastasis by
negatively regulating Src/ERK activation, resulting in increased E-cadherin
expression and β-catenin retention [112]. Prx2 overexpression also reduces the
chances of TGF-β1 induced EMT and cell migration in colorectal cancer cells
[113]. It is interesting to note that the effect of Prx2 on TGF-β1 induced EMT in
colorectal cancer cells is exactly opposite to the effect of Prx1 on the same
signaling pathway in A549 cells, which is discussed earlier in this review and
depicted in Figure 1-4. However, it is not clear yet whether these activities are
regulated in a tissue-specific manner or they co-exist in the same cancer type.
1.1.5.4 Prx3 in cell-signal transduction and tumorigenesis

Prx3 is primarily a mitochondrial Prx. The expression of Prx3 is enhanced by
SirT1 in partnership with FoxO3a and PGC1α, and the absence of either leads to
its down-regulation [114]. SirT1 enhances the complex formation of FoxO3a with
PGC1α and this complex regulates the expression of Prx3 as well as multiple
other antioxidant proteins [114]. Prx3 expression is also regulated by superoxide
dismutase through an unknown mechanism [115]. Prx3 is a downstream target of
c-Myc transcription factor and it acts as a major mediator for the regulation of cMyc functions in cell transformation, tumor progression, and apoptosis [116]. In
medulloblastoma, Prx3 is a target of MiR-383 (a microRNA), and its expression
reduces cell proliferation [117]. In cervical cancer, Prx3 is over-expressed and its
levels are correlated with an increased rate of cell proliferation [118]. Single
nucleotide polymorphism RS7082598 of the PRDX3 gene is correlated with a
reduced risk of cervical cancer [119]. In lung squamous cell carcinoma, Prx3 is
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over-expressed along with increased Srx in an Nrf2 dependent manner, which
indicates a potentially important role of the Srx-Prx3 axis in these tumors [74].
1.1.5.5 Prx4 in cell-signal transduction and tumorigenesis

Prx4 is the fourth member of typical 2-Cys Prx family and resides mainly in
endoplasmic reticulum. There is also a low molecular weight secreted form of
Prx4 that can be found in extracellular matrix and plasma. Although there are a
few reports about the post-transcriptional regulation of Prx4, how this protein is
regulated at the transcriptional level is yet to be studied. Calpain (a calciumdependent cysteine protease) can enhance the expression of Prx4 through posttranscriptional regulation [120].
Besides its regular antioxidant function, Prx4 also mediates the oxidative folding
of various endoplasmic reticulum proteins through its chaperone function.
Chaperone function is accomplished through cooperation with protein disulfide
isomerase [121]. Data in our lab indicate that Prx4 is susceptible to
hyperoxidation at very low levels of oxidative stress. Hence, the chaperone
function of Prx4 may be facilitated at lower oxidative stress levels. Prx4 improves
insulin synthesis by enhancing the endoplasmic reticulum folding of insulin and
thus improves pancreatic β-cell function [122]. In pancreatic cancer, Prx4 is
reported to be down-regulated [67]. However, it is not clear whether the Prx4
down regulation is a cause or effect of pancreatic cancer. Expression of Prx4
promotes the metastatic potential of lung adenocarcinoma cells [86]. Prx4 along
with Srx increases RAS-RAF-MEK signaling by enhancing intracellular
phosphokinase signaling [32]. The RAS-RAF-MEK pathway is well-known for
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controlling cancer cell proliferation and metastasis in various types of cancer.
Therefore, the ability of the Srx-Prx4 system to modulate this pathway indicates
their importance in cancer development. The exact mechanism of regulation of
RAS-RAF-MEK pathway by Srx or Prx4 is not identified yet. Theoretically, a ROS
dependent mechanism may be involved since Srx restores the antioxidant
function of Prx4 [32]. Moreover, Prx4 is a downstream mediator of Srx in lung
cancer development. The Prx4 knockdown recapitulates the phenotypes of Srx
knockdown cells (i.e. reduction in anchorage independent colony formation, cell
migration, and invasion) [32]. There are a few other typical 2-Cys Prx-isoforms
that may have similar effects in other pathological or physiological conditions, but
such a strong relationship of Srx with other Prx is not reported yet. Furthermore,
Prx4 is over-expressed in the majority of cancers where Srx is overexpressed
(refer to Table 1-1) [67]. In prostate cancer, over-expressed Prx4 enhances the
rate of cell proliferation [123]. In oral cavity squamous cell carcinoma, expression
of Prx4 enhances cancer metastasis [124]. In colorectal cancer, high expression
of Prx4 correlate with poor survival of patients [125]. As mentioned before, Srx is
also highly expressed in colon cancer and is required for chemical-induced colon
carcinogenesis [34]. Therefore, it may be of interest to study the significance of
Srx and Prx4 in colon cancer.

1.1.6 Summary and future directions
The Srx-Prx axis plays a critical role in a variety of physiological and pathological
conditions involving redox signaling. Some information is available about crosstalk between the Srx-Prx axis and other signaling pathways. However, the factors
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that affect this cross-talk are largely unknown. The way an individual isoform of
Prx contributes to different signaling pathways remains elusive. It is necessary to
differentiate the contributions of the antioxidant function of Prx and its molecular
chaperone function in terms of their impact on signal-transduction. Further
research will help to unravel the list of proteins whose folding is assisted by Prx.
Such research will provide a direction to identify different signaling pathways that
are modulated by the chaperone function of Prx. Classification of signaling
pathways regulated by chaperone and antioxidant functions of Prx will help us
design a better targeting strategy against Prx in tumor cells. Prx is clearly shown
to play a protective role in cardiovascular and neurological diseases. However,
its role in cancer is still controversial due to both tumor-suppressor and
oncogenic roles played by Prx-isoforms in different cancer types. Special
attention needs to be paid to the mechanism by which the same Prx-isoform can
play different, and sometimes opposite roles in different cancer types. Posttranslational modifications of Prx may be one of the mechanisms that contribute
to the dual behavior of Prx. Other possible explanations may include the
presence of allelic variants or single nucleotide polymorphism of the Prx genes.
More in-depth mechanistic studies in the future will help to unravel the
interweaved behavior of Prx and lead to development of better therapeutic
strategies for cancer prevention or treatment.
The Srx itself plays an oncogenic role in many types of cancer, including skin,
colon, and lung cancer, to name a few. The biochemistry of Srx function has
been studied in great detail. However, discerning the role of Srx in
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carcinogenesis requires a deeper understanding that can only be fulfilled by
future research. Considering the oncogenic role of Srx, it will be worth exploring
Srx inhibitors as molecules of choice for chemoprevention and/or chemotherapy.
Our existing understanding of the Srx-Prx interaction can help in designing good
targeting strategies against Srx. However, more details regarding Srx
deglutathionylation activity will be of great help for defining future directions. The
hydrophobic pocket of Srx or other amino acids present at the Srx-Prx interface
can be defined as a target for inhibitor screening. Virtual screening tools and
other computational methods of drug-discovery can help reduce the cost and
time required for identifying a good inhibitor. In short, Srx can be explored as a
therapeutic target in cancer and targeting Srx using small molecules can be a
valuable strategy for development of future chemotherapeutic molecules.
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1.2 Scope of dissertation
1.2.1 Hypothesis
The majority of Srx functions are mediated through the Srx-Prx interaction.
Previous publications from our research group have demonstrated the oncogenic
role of the Srx-Prx interaction in tumor promotion and metastasis. The general
hypothesis of the research described in this dissertation is that Srx plays a critical
role in lung carcinogenesis and targeting the Srx-Prx axis or Srx alone may
facilitate future development of targeted therapeutics for prevention and
treatment of human cancer.

1.2.2 Specific aims
To test the stated hypothesis, the following specific aims were designed:
Specific Aim 1: Demonstrate that Srx enhances urethane-induced lung
carcinogenesis.
Specific Aim 2: Demonstrate the molecular domains in Srx and Prx that can be
used as a target site to modulate Srx-Prx interaction or inhibit Srx.
Specific Aim 3: To demonstrate the potential of ISO1 as an inhibitor of the SrxPrx interaction.
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CHAPTER 2: EFFECT OF SULFIREDOXIN DEPRIVATION ON THE
URETHANE-INDUCED LUNG TUMORIGENESIS
2.1 Synopsis
Sulfiredoxin (Srx) is the exclusive enzyme that reduces the over-oxidized form of
typical 2-Cys peroxiredoxins (i.e. Prx1-4). It has been found to be over-expressed
in human non-small cell lung cancer. Cigarette smoke induces lung
carcinogenesis and is a mixture of multiple carcinogens that work together to
promote tumorigenesis. Urethane is a component of cigarette smoke and has
been known to induce lung tumors in mice. We first tested the effect of cigarette
smoke condensate on Srx expression in vitro. Both cigarette smoke and
urethane induced Srx expression in vitro. To study the effect of Srx on lung
tumorigenesis in vivo, we tested the effect of Srx-knockout on urethane-induced
lung tumorigenesis in mice. Srx knockout mice were generated on FVB
background and lung tumorigenesis was induced by urethane protocol. We found
significantly lower tumor multiplicity in Srx knockout (Srx-/-) mice compared to
wild type (Srx+/+) or heterozygous (Srx+/-) siblings. Urethane treated BEAS2B
cells

indicated

increased

expression

of

Srx,

Prx1,

Prx2,

and

Nrf2.

Histopathological analysis revealed that loss of Srx decreases tumor cell
proliferation and enhances apoptosis. This data indicates that loss of Srx protects
mice against urethane-induced lung tumorigenesis. Hence, Srx has a critical
oncogenic role in lung tumorigenesis.
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2.2 Introduction
Sulfiredoxin (Srx) is an exclusive enzyme that reduces over-oxidized typical 2Cys peroxiredoxins [24]. Srx utilizes ATP and magnesium (Mg2+) or manganese
(Mn2+) as cofactors and forms sulfinic phosphoryl ester followed by thiosulfinate
intermediate to reduce over-oxidized Prx [24, 126]. Srx is evolutionarily
conserved in the majority of eukaryotes, but is rare in prokaryotes, with few
exceptions (e.g. cyanobacteria). Apart from its antioxidant function, Srx can
catalyze the deglutathionylation of actin, Prx2, and protein phosphatase [45, 53].
There may be other unidentified substrates that are deglutathionylated by Srx.
Biochemistry of the Srx-Prx interaction and enzymatic activity of Srx has been
studied in great detail (please refer to chapter 1); however, the physiological and
pathological significance of Srx has not been fully revealed. Srx expression is
altered in many types of human cancer. Our previous work has demonstrated
oncogenic association of Srx with skin, colon, and lung tumorigenesis, where it is
found to be highly over-expressed in tumors compared to adjacent normal tissue
[32, 34, 78, 86, 127].
Lung cancer is the leading type of cancer-related deaths worldwide [128, 129].
Smoking multiplies the risk of lung cancer according to amount and quality of
exposure. To understand the effect of cigarette smoke on antioxidant protein
expressions, we treated BEAS2B cells with cigarette smoke condensate (CSC)
and studied its effect on the expression of various antioxidant proteins. CSC
induced expression of various antioxidant proteins, including Srx. Cigarette
smoke is a complex mixture of more than 5,000 chemicals [130]. To further study
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the effect of cigarette smoke on tumorigenesis, we decided to test one of its
components, urethane, which is a well-known lung carcinogen [131, 132].
Urethane is also present in a variety of fermented food and beverages, including
alcoholic beverages [133]. Urethane-induced lung carcinogenesis is a wellestablished model in mice. Mechanistic studies identified Nrf2, AP-1, STAT3, and
many other oxidative stress induced proteins as mediators of urethane’s
carcinogenic activity [134, 135]. Previous studies have indicated that oxidative
stress related induction of Srx expression is mediated through Nrf2 as well [69,
78]. Therefore, we hypothesized that Srx may be a mediator of urethane-induced
lung cancer. Whether Srx is involved in urethane-induced lung carcinogenesis
has not yet been studied. Therefore, we studied the functional significance of Srx
in urethane-induced lung carcinogenesis. We used Srx knockout mice and a
well-established urethane-induced lung carcinogenesis model for this study. The
model provides an important experimental strategy to study the pathological
significance of Srx in urethane-induced lung carcinogenesis. Our data suggest
that loss of Srx protects mice from urethane-induced lung tumorigenesis.

2.3 Materials & methods
2.3.1 Cell culture and western blot
Human lung/bronchus epithelial BEAS2B cell line was commercially obtained
from American Type Culture Collection (ATCC; Manassas, VA). Cells were
cultured in our laboratory less than 6 months after resuscitation. All experiments
were conducted with BEAS2B cells within 10 passages in 6 months. Cells were

32

maintained in Dulbecco's Modified Eagle Medium (DMEM) (Lonza Walkersville,
Inc., Walkersville, MD) containing 5% fetal bovine serum.
Cigarette smoke condensate was obtained from Dr. Chandra Gary Gairola’s
laboratory at the University of Kentucky. Urethane and N-acetyl cysteine were
commercially obtained from Sigma-Aldrich (St. Louis, MO). The cells were
treated with CSC concentrations of 10 μg/mL, 20 μg/mL, and 40 μg/m for 48 hours.
To mimic chronic exposure to urethane from a variety of food, beverages, and
cigarette smoke, we treated cells with urethane for 5 days. The media was
changed daily and fresh urethane added each time the media was changed. For
western blot, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
containing protease inhibitors (Santa Cruz Biotech, Dallas, TX). Protein bands
were separated using sodium-dodecyl sulfate-polyacrylamide gel electrophoresis
and western blotting was performed following standard protocol. The primary
antibodies used included anti-Srx (Proteintech, Chicago, IL; Catalog 14273-1AP), anti-Prx I (Abcam, Cambridge, MA; Catalog ab41906), anti-Prx II (Santa
Cruz Biotech; Catalog SC-33574), anti-Prx III (Santa Cruz Biotech; Catalog SC59661), anti-Nrf2 (Santa Cruz Biotech; Catalog SC-722), anti-Prx IV (Abcam;
Catalog ab133872), anti-p-c-Jun (Cell Signaling, Billerica, MA; Catalog 9261L)
and anti-β-actin (Sigma–Aldrich; Catalog A2228).

2.3.2 Quantitative reverse transcription and polymerase chain reaction
BEAS2B cells were treated with CSC or urethane. Vehicle treated cells were
used as control. RNA was extracted using the RNeasy Kit (Qiagen, Valencia,
CA). RNA (200 ng) was used for cDNA synthesis and polymerase chain reaction
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(PCR). The following primers were used in the process: mSRX forward 5’- AAA
GTG CAG AGC CTG GTG G-3’, mSRX reverse 5’-CTT GGC AGG AAT GGT
CTC TC-3’; mNRF2 forward 5’-AGT GGA TCT GCC AAC TAC TC-3’; mNRF2
reverse 5’-CAT CTA CAA ACG GGA ATG TCT G-3’; mPrx1 forward 5’- ACC
TCT TCC TGC GTT CTC AC-3’, mPrx1 reverse 5’-TGT CCA TCT GGC ATA
ACA GC-3’; mGAPDH forward 5’-ACA ACT TTG GCA TTG TGG AA-3’,
mGAPDH reverse 5’-GAT GCA GGG ATG ATG TTC TG-3’. Reverse
transcription and PCR were carried out using standard protocol [78]. The PCR
product was mixed with SYBR green and 6X running buffer. This mixture was run
on 3% agarose. The bands were quantitated using ImageJ software 1.49.
Quantitative results were normalized by level of GAPDH mRNA.

2.3.3 Lentiviral ShRNA knockdown of Srx in BEAS2B cells
BEAS2B cells were treated with 5 mM urethane for 3 generations. This treatment
induced expression of Srx and other antioxidant proteins in those cells. ShRNAbased knockdown experiments were planned and performed according to
previously published methods [86]. All ShRNA constructs, including MISSION®
pLKO.1-puro control vector (vector control), MISSION® non-target shRNA
(ShNT), and ShRNAs specifically targeting Srx (ShSrx), were commercially
obtained (Sigma-Aldrich). Commercial sequencing services were utilized to
confirm the sequence. Lentiviral particles expressing ShRNA were produced in
HEK293T cells using the provider’s plasmid packaging system and FuGENE 6
transfection reagent following suggested transfection and virus production
procedures. The titer of virus-containing medium was determined by measuring
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the level of p24 using ELISA and Lenti-X GoStix kits (Clontech, Mountain View,
CA). To establish stable knockdown, urethane-treated BEAS2B cells were
infected with lentiviral particles. Cells were subsequently maintained in
puromycin-containing medium to establish stable cells.

2.3.4 Soft agar colony formation assay
BEAS2B cells were treated with 5 mM and 10 mM urethane for 5 days. The
control group was treated with phosphate buffer saline (PBS) as vehicle control.
Each of these groups was harvested and cell numbers were counted using a
LunaTM automated cell counter. The cells were suspended in 0.3% agar. The cell
culture (6-well) plates were pre-coated with 1 mL of 0.6% agar and 15,000 cells
were plated per well for each group. Urethane was added to the treatment group
and PBS to the vehicle control group 24 hrs after plating. Medium was changed
every 4 days and fresh urethane/vehicle was added each time the media was
changed. The plates were incubated for 6 weeks. The soft agar colonies were
stained using 0.25% crystal violet staining and images were taken using
Amscope 3.7 software with a digital camera. The size and number of colonies
were counted using OpenCFU 3.8.11 software.
To study the role of Srx in the urethane-induced BEAS2B cell transformation, we
knocked-down Srx expression in urethane-treated BEAS2B cells using the
lentiviral method. The BEAS2B cells were first treated for 3 generations with 5
mM urethane to enhance Srx expression. These cells were subjected to lentiviral
infection to knockdown Srx. Vector-infected cells were used as control. These
cells were subsequently maintained on 5 mM urethane along with puromycin35

containing media to get stable transfection. Srx expression in non-treated
BEAS2B cells, along with multi-generation urethane-treated ShV and ShSrx cells
were measured using western blot. We carried out the colony formation assay
after stable knockdown was confirmed. Both ShVector (empty vector transfected)
and ShSrx (Vector loaded with Srx shRNA transfected) cell colonies were treated
with 5 mM urethane and puromycin throughout the incubation period. The rest of
the procedure was the same as the procedure used for normal BEAS2B cells.

2.3.5 Srx knockout mice genotyping
Mouse breeding and animal protocols were performed following the guidelines of
the University of Kentucky’s Institutional Animal Care and Use Committee. Srx
knockout mice were generated on FVB background using Srx-/- B6/129 mice
backcrossed onto an FVB mice strain [34]. After backcrossing on FVB
background for seven generations, the inbred offspring were used for
experiments. Genomics DNA from tail clip was extracted using genomic DNA
extraction kit (Qiagen). This genomic DNA was used for PCR-based genotyping
as previously reported [136].

2.3.6 Urethane protocol
A randomized double-blind experimental design was applied to eliminate
potential subjective bias. Briefly, mice at 7 week of age, including wild type (Wt),
heterozygous, and knockouts, were given once weekly intraperitoneal injection
for 3 weeks, with 1 mg/g body weight of urethane (Sigma-Aldrich) dissolved in
saline [137, 138]. The mice were weighed before every administration of
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urethane during the first 3 weeks. After the third administration of urethane, mice
were weighed once weekly. Mice were maintained on a normal diet and ad
libitum water for 10 weeks following the first injection. During this period of 10
weeks, mice with signs of severe suffering were euthanized. At the end of 10
weeks, all mice were humanely sacrificed. Mouse lungs were perfused with PBS
followed by multiple rinses in PBS. Tumors were counted using a magnifying
glass. This counted all the tumors on the surface of lung. Mouse lungs were fixed
in 4% paraformaldehyde and stored in 70% ethanol before being processed with
standard paraffin embedding and sectioning. For histological assessment, all
lobes of each lung were sectioned for 15 slides and the first slide was stained by
hematoxylin and eosin (H&E) staining.

2.3.7 Immunohistochemistry staining and in situ apoptosis assay
Immunohistochemistry was performed using Vectastain Elite ABC kit #PK-6100
(Vector Laboratories, Inc., Burlingame, CA) with hematoxylin counterstaining.
Antibodies used include anti-Srx (1:200, Proteintech, Chicago, IL; Catalog
14273-1-AP), anti-Prx1 (1:300, Abcam, Cambridge, MA; Catalog ab41906), antiNrf2 (1:200, Santa Cruz Biotech, Inc., Dallas, TX; Catalog SC-722) and anti-Ki67
(1:20, Abcam, Cambridge, MA; Catalog ab16667). Terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL) assay was performed
using TACS 2TdT-DAB In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg,
MD) to assay apoptosis in mouse lung. Following manufacturer’s protocol, all
samples were counterstained with methyl green, dehydrated, and mounted
before microscopic visualization. Images of immunohistochemistry were taken
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using a digital camera with AmScope 3.7 software attached to a Zeiss Axioplan 2
Imaging microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY). The IHC
images were quantitated using the Aperio Imagescope and the quantitative
values were plotted in the form of bar graph for comparison.

2.3.8 Statistical analysis
Quantitative data were presented as sample mean ± standard deviation (x� ± SD).

Data were analyzed with the indicated statistical methods using SigmaPlot

(version 13.0). For calculation of the p-value, parameters of two-tailed 95%
confidence interval were used for all analyses. A p-value of ≤0.05 was
considered statistically significant.

2.4 Results
2.4.1 CSC enhances the expression of antioxidant proteins
BEAS2B cells were selected to study the effect of urethane on protein expression
as they are an immortalized normal (non-cancer) lung cell line that is considered
suitable to study chemical-induced carcinogenesis of lung cells. BEAS2B cells
(human lung Broncho epithelial cell line) were treated with CSC at concentrations
of 10 µg/mL, 20 µg/mL, and 40 µg/mL. The two higher concentrations
significantly enhanced expression of Srx and other antioxidant proteins after 48
hours of treatment (Figure 2-1A & B). The expression of all Prx (except Prx3)
showed significant increase in concentration at all 3 concentrations. The Prx3
expression did not show significant increase in expression. We further tested
whether this over-expression of the Srx-Prx axis is mediated by oxidative stress.
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Figure 2-1: Cigarette smoke condensate (CSC) induces the expression of
antioxidant proteins: CSC increases the expression of Srx, Prx, and Nrf2 in a
dose-dependent manner and this effect can be reversed by co-exposing cells
with N-acetyl cysteine: (A) western blot and (B) quantification graph showing
expression of different proteins in BEAS2B cells treated with CSC for 48 hours;
(C) western blot and (D) quantification graph showing the effect of N-acetyl
cysteine on CSC-induced protein expression. The statistical significance is
achieved for differences in all three treatments compared to control in panel (B)
and both NAC treated group compared to CSC only group in panel (D).
Statistically significant difference was not observed in case of Prx3. One way
ANOVA followed by Holm-Sidak post hoc test was utilized to test statistical
significance (p≤0.05).
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We co-treated a group of BEAS2B cells with N-acetyl cysteine (antioxidant) along
with CSC for 48 hours. N-acetyl cysteine reversed the enhanced expression of
these proteins (Figure 2-1C & D). Hence, CSC-induced overexpression of the
Srx-Prx axis is mediated through oxidative stress. To confirm whether the
regulation of protein expression is at a transcriptional or translational level, we
studied the mRNA expression of individual proteins using reverse transcription
followed by polymerase chain reaction (RT-PCR). The RT-PCR results indicated
increased transcription of antioxidant proteins (Figure 2-2A & B). The highest
increase in transcription was observed in Nrf2, Srx, and Prx1; transcription of
Prx2 and Prx4 increased to a lesser extent. On comparing the changes in protein
expression with mRNA expression, we found that the effect of CSC on protein
expression was much stronger than its effect on mRNA expression. Hence, apart
from transcriptional regulation, there can be other mechanisms by which CSC
enhances protein expression.

2.4.2 Urethane enhances expression of antioxidant protein
Urethane is a component of cigarette smoke and fermentation products. We
selected urethane to confirm whether it can enhance Srx expression in the same
way as CSC. To mimic chronic human exposure conditions, we treated BEAS2B
cells with urethane for 5 days. This 5-day chronic treatment induces the
expression of sulfiredoxin in a dose-dependent manner (Figure 2-3 A&B).
Urethane also enhances the expression of typical 2-Cys Prxs, especially Prx1
and Prx2. The levels of over-oxidized Prxs (i.e., Prx-SO3) were also found to be
enhanced in urethane treated cells too.
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Figure 2-2: Cigarette smoke condensate regulates the transcription of the
Srx and Prx: Cigarette smoke condensate transcriptionally regulates the
expression of antioxidant transcripts. (A) RT-PCR gel showing mRNA expression
of individual proteins; (B) graph showing quantification of bands. T-test was
applied to analyze the statistical difference in mRNA expression (*p ≤ 0.05).
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Figure 2-3: Urethane treatment enhances antioxidant protein expression in
BEAS2B cells: (A & B) Effect of urethane on protein expression; (C&D) effect of
urethane on mRNA expression; (E&F) effect of trigonelline on urethane-induced
protein expression. One-way ANOVA on Ranks followed by Dunn’s test was
applied for analysis of protein expression. T-test was applied to analyze the
statistical difference in mRNA expression (*p ≤ 0.05).
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On comparison on increase in total Prx expression to increase in Prx-SO3
expression, we concluded that Prx-SO3 expression probably due to increased
levels of total Prx and not due to higher oxidation of Prxs. Nrf2 signaling can be
considered the most plausible mechanism of Srx and Prx1 induction by urethane
treatment, as Srx was found to have higher expression in urethane-treated cells
compared to control. The expression of Prx3 and Prx4 did not change
substantially after 5 days of urethane treatment. To confirm the mechanism of
Srx and Prx1 induction we next carried out reverse transcription-polymerase
chain reaction. BEAS2B cells treated urethane for 5 days showed increase in
mRNA transcription of antioxidant proteins (i.e. Srx, Prx1 and Nrf2). The increase
in mRNA expression in the group treated with 5mM urethane was found to be
statistically significant (two tailed t-test, p≤0.05) for Nrf2 and Srx, but not for Prx1
compared to respective non-treated BEAS2B control (Figure 2-3 C&D). Similar to
CSC treatment, the effect of urethane on protein expression was stronger
compared to its effect on mRNA expression. Ergo, there can be nontranscriptional mechanisms by which urethane can regulate the expression of
these proteins.
Earlier literature has indicated that the Nrf2 enhances the Srx transcription.
Hence, a Nrf2 inhibitor should reduce the Nrf2 induced Srx and Prx1 expression.
We studied the effect of trigonelline (Nrf2 inhibitor) on Srx and Prx1 expression in
urethane treated cells. Trigonelline inhibited Srx expression in urethane treated
cells (Figure 2-3 E & F). It confirms that urethane-induced Srx expression is
mediated through Nrf2. Trigonelline inhibited Prx1 expression to a lesser extent.

43

Hence, urethane-induced Prx1 expression is (at least partially) mediated through
Nrf2.

2.4.3 Urethane treatment transforms BEAS2B cells in an Srx-dependent
manner
After confirming the effect of urethane treatment on protein expression, we tested
the effect of this treatment on BEAS2B cell transformation. Our initial study
indicated that 5-day urethane treatment induces Srx expression in BEAS2B cells.
Therefore, we initially treated cells for 5 days with 5 mM or 10 mM urethane,
followed by treatment in soft agar plate with respective urethane concentrations
or vehicle (phosphate buffer saline)-treated control. As expected, the vehicletreated control group showed low anchorage-independent colony formation.
However, the urethane-treated group produced multiple colonies. The numbers
of colonies were higher in the 10 mM urethane-treated group compared to the 5
mM urethane-treated group, which indicates the dose-dependence of urethane’s
effect (Figure 2-4A & C). Statistically significant differences were observed in a
number of colonies in the 10 mM urethane-treated group (but not the 5 mM
urethane-treated group) compared to vehicle-treated control.
To study the role of Srx in the urethane-induced BEAS2B cell transformation, we
studied the effect of Srx-knockdown on colony formation in the urethane-treated
cells. The cells treated with urethane for multiple generations followed by Srx
knockdown showed lower incidences of colony formation compared to vector
infected control (Figure 2-4 B & D). Hence, urethane induced cell transformation
is mediated through induction of Srx expression.
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Figure 2-4: Urethane transforms BEAS2B cells in an Srx-dependent
manner: Urethane enhances anchorage independent cell growth in a dosedependent manner (A & C). Urethane-induced cell transformation is partially
mediated through Srx, as knockdown of Srx results in reduced potential of colony
formation (B & D). Each treatment group represents data from triplicates (n= 3).
Statistical methods used were (C) one-way ANOVA and Holm-Sidak post-hoc
analysis (*p ≤ 0.05), and (D) t-test (*p ≤ 0.05)
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Srx-knockdown reduced the number of small and large colonies compared to
vector control. The differences in number of colonies were statistically significant
(p ≤ 0.05) irrespective of colony size. Hence, our data shows that urethane
transforms BEAS2B cells and enhances anchorage-independent colony
formation. Our data also confirms that the aforementioned transformation is
partially reversible by knockdown of Srx. Hence, Srx plays an important role in
urethane mediated cell transformation of BEAS2B cell.

2.4.4 Srx knockout mice are resistant to urethane-induced lung cancer
Srx knockout mice on FVB background were completely normal under normal
laboratory conditions. To study the role of Srx in in vivo lung tumorigenesis, a
well-established urethane-induced mouse lung tumorigenesis protocol was
applied (Figure 2-5A). Mean mouse weight was plotted on a time scale. Srx
knockout and heterozygous mice showed a statistically significantly (p<0.001)
better weight profile compared to wild type mice (Figure 2-5B). The differences in
weight profile over weeks were not statistically significant between heterozygous
and knockout mice groups (p=0.148). To minimize mouse suffering, all mice were
humanely sacrificed 10 weeks after the first urethane administration.
We examined the tumor incidence in mice lungs. Representative images of mice
lungs with tumors and H&E staining of tumors are shown (Figure 2-6A & C). All
mice had lung tumors at this stage. The number of tumors was counted using a
magnifying glass. The intra-tissue tumors limited the detection of those tumors.
However, they should follow the same pattern as the surface tumor while
comparing the effect of Srx expression.
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Figure 2-5: Srx null mice are resistant to urethane toxicity: (A) Schematic
presentation of the urethane protocol; (B) effect of urethane treatment on mouse
body weight. The Srx genotype did not affect weights of non-treated mice.
Statistical methods used were two-way ANOVA and Holm-Sidak post-hoc
analysis (*p ≤ 0.05).

47

48

Figure 2-6: Srx null mice are resistant to urethane-induced carcinogenesis: (A) Whole lung tissue; (B) 10X
images of Hematoxylin and Eosin stained mouse tumors; (C) average tumor multiplicity in Srx Wt, Het, and
knockout mice, (D) average tumor size in Srx Wt, Het, and knockout mice. We started with equal number of mice in
each group. Due to mice fighting and injury, few mice needed to be sacrificed. Hence, we had different number of
lungs in different genotype. The dots above and below error bars indicate outliers (C & D). Statistical methods used
were one-way ANOVA (C-D) and Holm-Sidak post-hoc analysis (*p ≤ 0.05).

The number of tumors per lung tended to be lower in Srx knockout (-/-) mice
compared to wild type (p=0.001) or heterozygous (p=0.012) mice (Figure 2-6C).
The average tumor multiplicity in Srx knockout mice was reduced by
approximately 2-fold compared to wild type mice. Smaller tumor size and tumor
location hindered accessibility for measurement of tumor diameter. Therefore, we
used the longest diameter of each tumor from the H&E stained slides. These
tumor diameters (µM) were used for comparison of tumor sizes in all three
groups. The average diameter in Srx knockout mice tended to be lower than wild
type and heterozygous mice, although statistically significant differences were
found only on comparison of wild type with knockout mice (p= 0.022) as opposed
to wild type vs. heterozygous (p=0.199) or heterozygous vs. knockout (p=0.174)
mice (Figure 2-6D). Our data indicate that Srx knockout mice had a significant
reduction in tumor multiplicity and tumor diameter compared with their wild type
or heterozygous counterparts. Therefore, these data suggested that genomic
loss of increases the mice resistance to urethane-induced lung tumorigenesis.

2.4.5 Urethane induces the expression of antioxidant proteins in mouse
lung
To investigate why Srx depletion in mice led to lower tumor multiplicity, we
examined the effect of urethane treatment on the expression of Srx in mouse
lung tumors. An immunohistochemical method that specifically detected Srx in
formaldehyde-fixed tissue was applied as previously reported [139]. Previous
reports from our group indicate that Srx is barely detectable in normal human
lung tissue. After urethane treatment, the majority of lung tissue, including tumor
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tissue from Srx (+/+) or (+/-) mice, showed strong positive Srx-staining (Figure 27A). There were differences in strength of staining in Wt vs. Het mouse tissue as
well, with Wt showing stronger staining. Lack of positive staining in the lung and
tumors of Srx knockout mice further validated the specificity of anti-Srx staining
(Figure 2-7A & D). We also tested Prx expression in these lungs and found
positive staining for Prx1 (Figure 2-7B&E). Prx expression was lower in Srx+/and Srx-/- mice compared to Srx+/+ mice.
As Nrf2 transcriptionally up-regulates the expression of Srx as well as Prx1, we
stained these lung tumors for Nrf2 using specific antibody. Our data confirmed
the expression of Nrf2 in urethane-treated tumors (Figure 2-7C&F). The
expression of Nrf2 was higher in Srx+/- and Srx-/- mice compared to Srx+/+
mice. These data suggest that application of urethane led to increased
expression of antioxidant proteins in mouse lung and tumors.

2.4.6 Depletion of Srx reduced cell proliferation and increased apoptosis in
the urethane treated groups
To identify the reasons behind reduction of tumor multiplicity and diameter in Srx
knockout mice, we further investigated the effect of Srx depletion on cell
proliferation and apoptosis. Mouse lung tumors from all three genotypes were
stained with Ki67 (a cell proliferation marker). There was an enhanced staining
for Ki67 in tumors from wild type mice as opposed to knockout and
heterozygous, where the Ki67 staining was significantly lower (Figure 2-8A). The
positive nucleus were counted using Aperio Imagescope software and plotted for
quantitative comparison.
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Figure 2-7: Immunohistochemistry staining showing expression of different
proteins
in
urethane-treated
lung
tissue:
20X
images
of
immunohistochemistry indicating expression in lung tumor from mice lungs of
different Srx genotypes: (A) Srx, (B) Prx1, and (C) Nrf2. The staining was
quantitated using Aperio Imagescope software. Quantitative values of 3,3′diaminobenzidine (DAB) staining estimation are plotted for (D) Srx, (E) Prx1, and
(F) Nrf2 expression. Statistical methods used were one-way ANOVA on Ranks
and Dunn’s post-hoc analysis (*p ≤ 0.05).
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Figure 2-8: Srx enhances tumor cell proliferation and reduces tumor cell
apoptosis in urethane-induced lung carcinogenesis: (A) 20X images of Ki67
staining as a tumor cell proliferation marker in tumors from different Srx genotype
mice; (B) 20X images of TUNEL staining as an indicator of tumor cell apoptosis
in tumors from different Srx genotype mice. The number of positive nucleus was
quantitated using Aperio Imagescope software. (C) quantitative comparison of
tumor cell proliferation index (Ki67 staining); (D) quantitative comparison of tumor
cell apoptosis (TUNEL staining). Statistical methods used were one-way ANOVA
(C & D) and Holm-Sidak post-hoc analysis (*p ≤ 0.05)
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Quantitatively, the difference in cell proliferation was statistically significant with a
significantly lower number of positive nuclei in knockout (p<0.001) and
heterozygous (p=0.006) compared to wild type mice (Figure 2-8A & C). A
statistically significant difference could not be observed in Ki67 positive nuclei
between the knockout vs. heterozygous groups.
We also examined intra-tumoral apoptosis using TUNEL staining. There were
enhanced TUNEL positive cells in tumors from knockout mice as opposed to wild
type and heterozygous (Figure 2-8B & D). Quantitatively, the differences in
TUNEL positive nuclei were statistically significant with a significantly higher
number of positive nuclei in knockout compared to wild type (p<0.001) as well as
heterozygous (p=0.001) mice. Differences between TUNEL staining in
heterozygous and wild type mice were not statistically significant.

2.5 Discussion
The primary function of Srx is to reduce over-oxidized Prxs in host cells. Protein
deglutathionylation is an alternative function [22]. Cellular antioxidants, such as
glutaredoxin, Prx, Trx, and Trx-like proteins, as well as Srx, have been identified
as over-expressed in a wide range of human cancers [69, 78, 140, 141]. These
antioxidants promote cell survival through regulation of oxidative stress. Cigarette
smoke is known to enhance susceptibility to lung cancer [142]. It is a complex
mixture of chemicals that has potential to induce lung carcinogenesis. Many
components of cigarette smoke act as direct or indirect lung carcinogens. We
first checked the effect of cigarette smoke on expression of the Srx and Prxs.
Cigarette smoke condensate enhanced the expression of Srx as well as
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individual Prxs (Figure 2-1). This action of CSC could be reversed with the
addition of chemical antioxidants such as N-acetyl cysteine. Hence, the effect of
cigarette smoke on expression of Srx-Prx axis components is at least partially
mediated through oxidative stress. This increase in expression of antioxidant
proteins was regulated at the transcriptional level (Figure 2-2). However, the
extent of change in mRNA expression is not as strong as the extent of change in
protein expression. This may be an indicator of non-transcriptional mechanisms
that cause the enhanced expression of Srx-Prx axis components in response to
CSC treatment.
To further investigate the effect of the Srx-Prx axis on lung cancer, we selected a
carcinogenic component of cigarette smoke. Urethane is a component of
cigarette smoke and a well-known lung carcinogen in mice [138]. However, the
urethane itself is not the carcinogen. Rather, urethane is metabolized to vinyl
carbamate epoxide, which later causes the majority of urethane toxicity [143].
These mechanisms of urethane-induced lung carcinogenesis along with our data
are summarized in Figure 2-9. Humans are mainly exposed to urethane from
alcoholic beverages [144]. Alcohol increases the expression of CYP2E1 [145],
which along with esterase are enzymes that play the main roles in metabolism of
urethane [146]. CYP2E1 converts urethane to vinyl carbamate epoxide, whereas
esterase converts it to ethanol [146]. Considering the stoichiometry of reaction,
the presence of alcohol has potential to slow down the metabolism of urethane
by esterase. Hence, the metabolism of urethane to vinyl carbamate epoxide
becomes the predominant mechanism of metabolism partially due to increased
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CYP2E1 expression and partially due to reduced rate of metabolism by esterase.
Cigarette smoke is another major source of urethane [131, 132]. Many
individuals consume alcohol and smoke cigarettes simultaneously [147]. This
trend of alcohol consumption along with smoking has increased in recent years.
Hence, the risk of urethane toxicity and urethane-induced lung cancer may be
higher in individuals who smoke and consume alcohol simultaneously. Human
lungs have a lower expression of urethane-metabolizing enzymes (i.e. CYP2E1)
and esterase, compared to other tissue like liver and gastrointestinal tract [148,
149]. This multiplies the risk of the aforementioned stoichiometric inhibition of
esterase in human lung. Hence, the risk of urethane conversion to carcinogenic
metabolite increases under regular exposure conditions where lungs are
simultaneously exposed to alcohol and cigarette smoke.
To study the role of Srx in lung carcinogenesis, we used the urethane model to
mimic lung cancer development in humans. Srx knockout mice were established
on an FVB background. Srx knockout mice were completely normal under
standard laboratory conditions. We demonstrated that depletion of Srx rendered
mice resistant to urethane-induced lung cancer, as Srx null mice showed
reduced tumor multiplicity and tumor diameter compared to wild type mice. Srx
null mice showed an almost 2-fold lower incidence of tumor multiplicity and
roughly 1.5-fold reduction in median tumor diameter. In mechanistic studies, we
found that Srx was strongly expressed in urethane-treated lung tumors and
depletion of Srx led to reduction in cell proliferation.
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Figure 2-9: Prospective mechanism of urethane-induced lung carcinogenesis: CYP2E1 (Pathway A) and esterase
(Pathway B) are the main enzymes that metabolize urethane. Pathway A predominates in metabolism of urethane as the
majority of urethane exposure to humans is from alcoholic beverages; Pathway B is stoichiometrically inhibited/slowed
down due to the presence of alcohol (an end product in Pathway B).

This study also demonstrates that depletion of Srx results in an enhanced rate of
intra-tumoral apoptosis. Reduced cell proliferation and increased intra-tumoral
apoptosis may contribute to the tumor-resistant phenotype of Srx knockout mice.
As per data from the American Cancer Society publication ‘Cancer Facts &
Figures’ and ‘Global Cancer Statistics’ reports, lung cancer is the leading cause
of cancer related deaths in the USA and worldwide irrespective of gender [128].
Identification of novel therapeutic targets for lung cancer is therefore very
important. Srx and Prx are highly expressed in human lung tumors. Srx
expression is critical for the pathogenesis of several human diseases, including
cancer. Our current and previous data clearly demonstrate that Srx plays a
significant pathogenic role in human cancer development. The cellular levels of
Srx may be regulated through AP-1 and Nrf2 [69]. In this study, we demonstrate
that urethane directly stimulates the expression of Srx, Prx, and Nrf2. Nrf2 is
involved in transcriptional regulation of Srx and Prx1 [69, 80]. Our data indicates
that urethane induces Srx and Prx1 expression at the transcriptional level. Earlier
researches as well as our current data indicate that Nrf2 acts as a mediator of
urethane-induced carcinogenesis [134]. Hence, our finding establishes that
urethane enhances Nrf2 expression and later transcriptionally regulates the
expression of Srx and Prx1. These findings further establish the role of Srx as a
mediator of urethane-induced lung carcinogenesis. Our findings of the tumorresistant phenotype of Srx knockout mice may reflect a long-term accumulative
effect of urethane exposure. It is not clear whether loss of Srx has any effect on
the mutagenic potential of urethane. Nevertheless, our findings suggest that Srx
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is one of the critical components that contribute to mouse lung tumorigenesis
in vivo. Targeting Srx may thus be employed as a novel strategy for lung cancer
prevention and/or treatment in the future.

2.6 Summary
Urethane is a well-established lung carcinogen with potential to induce
carcinogenesis in other tissues as well. It is a component of cigarette smoke and
alcoholic beverages. Alcoholic beverages are the main source of urethane
exposure for humans, while cigarette smoke is another major source. Vinyl
carbamate epoxide is a metabolite of urethane that is responsible for the majority
of its toxicities. Metabolism of urethane to vinyl carbamate epoxide is the
preferred method of urethane metabolism in the presence of alcohol. Hence, the
chances of urethane toxicity increase under normal human exposure conditions.
The role of Nrf2 in urethane-induced lung carcinogenesis has been documented
in the literature. This study identified the role of Srx in urethane-induced lung
carcinogenesis: urethane causes enhanced expression of Nrf2, leading to
transcriptional upregulation of Srx and Prx expression, in turn leading to lung
tumorigenesis. Knockdown of Srx in FVB mice partially protects mice against
urethane-induced lung tumorigenesis. The protection in Srx null mice is mainly
due to a reduction in tumor cell proliferation and increase in tumor cell apoptosis.
Hence, Srx plays an essential role in urethane-induced lung carcinogenesis and
can be considered a novel target for lung cancer prevention and/or treatment.
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CHAPTER 3: THE BIOLOGY OF SULFIREDOXIN (SRX)PEROXIREDOXIN1 (PRX1) INTERACTION: STRUCTURE TO
MOLECULAR INSIGHTS
3.1 Synopsis
Typical 2-Cys Prx is the group of Prx that is reduced by Srx. Srx-Prx1 interaction
is involved in pathogenesis of various oxidative stress-induced conditions,
including cancer, inflammation, cardiovascular disorders, and neurological
diseases. The purpose of this study was to understand the structural biology of
the Srx-Prx1 interaction, which may be of significance as a molecular target site
for a novel drug-discovery process. Homology modeling and protein-protein
docking approaches were applied to examine the Srx-Prx1 interaction using
in silico methods, including I-TASSER, Phyre2, Swissmodel, MZDOCK, and
ZDOCK. Using in silico studies, a 26-amino acid motif at the C-terminus of Prx1
was identified that may cause a steric hindrance for the kinetics of the Srx-Prx1
interaction. These findings were tested in vitro using purified recombinant
proteins, including Srx, Prx1, and Prx1Mutant (deleted C-terminal arm). We found
that deletion of the C-terminal arm of Prx1 significantly enhanced its association
with Srx (i.e. >1000-fold increase in ka) with minimal effect on dissociation (kd).
These results were further validated in Prx4. These data confirms that the cterminal arm of Prx is not required for Srx-Prx interaction. Taken together, these
data add novel structural insights critical for understanding the biology of the SrxPrx interaction.
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3.2 Introduction
The molecular characteristics of protein-protein interaction must be identified in
order to design an effective targeting strategy for inhibition of such interactions. A
3-dimensional structure of a protein and its individual components can play a
major or minor role in protein interaction. Understanding the molecular structure
of individual proteins is the first criteria that must be fulfilled to study the effect of
a 3-dimensional structure of individual proteins on protein-protein interaction.
Protein structure can be predicted experimentally using X-ray crystallography
and nuclear magnetic resonance studies. In the absence of experimental data, it
can be predicted computationally by homology modeling. Homology modeling is
one of the most popular methods for prediction of protein structures based on the
known structure of homologous proteins with some sequence identity [150]. It is
not trivial to predict the structure covering the full length of a protein using
experimental methods, as crystallizing the whole protein is a cumbersome task
that can be affected by myriad experimental factors leading to lower confidence
in the predicted structure. The relative ease of predicting the structure covering
the full protein sequence by homology modeling has led to popularity of this
method. Homology modeling has already established its utility in hypothesis
making for molecular studies [151, 152]. Protein structures predicted using this
method can be used computationally for protein-protein docking studies.
Protein-protein docking is a unique computational tool to identify the points of
contact during protein-protein interaction that can help in designing a targeting
strategy to inhibit those interactions [153]. Predictions of docking studies can be
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further confirmed experimentally using amino acid mutation and deletion studies.
Recombinant proteins can be designed with mutations at individual points of
contacts or deletion of a particular domain. These mutants can be used to study
the effect of particular mutations on protein-protein interactions. Once confirmed,
amino acids from these experiments can be defined as binding sites for proteinsmall molecule docking or virtual screening to identify the inhibitors of interaction.
We carried out protein-protein docking studies followed by deletion mutation to
confirm the role of the Prx C-terminal arm in Srx-Prx binding.

3.3 Materials and methods
3.3.1 Homology modeling and protein-protein docking studies
Although the structures of Prx and Srx are available in the Protein Data Bank,
none of the entries actually covers the full sequence of these proteins. Therefore,
homology modeling was used to predict the full-length structures of all Prx and
Srx. We used multiple online homology modeling programs in this experiment,
including I-TASSER (iterative threading assembly refinement) [154, 155], Phyre2
[156] and Swissmodel [157]. We used M-ZDOCK [158] for prediction of dimeric
structure from the monomeric structure predicted by I-TASSER and Phyre2.
Followed by homology modeling studies, we carried out protein-protein docking
studies using the ZDOCK [159] online server to identify structural characteristics
of interaction. We analyzed the final output of these experiments using PyMOL
visualizer and labeled the binding and catalytic site components.

61

3.3.2 Western blot and immunoprecipitation (IP) assay in HEK293T cells
HEK293T (human embryonic kidney) cells were transfected with pLV expression
vector for FLAG-tagged Srx. The stable transfection was ensured by maintaining
these cells on puromycin containing media. Cells were divided into three groups
and were treated with vehicle, 500 µM H2O2, or 1000 µM H2O2 for 10 minutes.
The vehicle treated group was used as control. The cells were lysed using RIPA
buffer for western blot and immunoprecipitation buffer for IP. The lysate were
incubated with anti-Srx antibody overnight at 4o C. Next morning magnetic beads
coated with anti-rabbit secondary antibody was incubated with samples for 2
hours. The sample was separated using magnetic bars. The beads were washed
3 times with fresh IP buffer. The protein was eluted using 1X LDS buffer buy
heating at 90o C for 10 minutes. Western blot was carried out using standard
procedures as described earlier in this dissertation.

3.3.3 Purification of recombinant proteins
Srx, Prx1wildtype, Prx1mutant (in which the last 22 amino acids from the C-terminal
were deleted), Prx4wildtype, and Prx4mutant were expressed in E. coli BL21(DE3)
cells using pRSET B vector. Srx was inserted between the BamHI and EcoRI
restriction sites of pRSET B. All the Prx wild type and Prx mutants were inserted
between BamHI and HindIII restriction sites of pRSET B. Coomassie blue
staining of different gels containing purified proteins is shown along with a
pRSET B vector map in Figure 3-1. All proteins had a (His)6 tag at the N-terminal.
BL21(DE3) cells were cultured at 37o C in LB broth media (Sigma-Aldrich).
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Figure 3-1: Protein purification using pRSET B vector: (A) Vector map; (B)
coomassie blue stained gels showing pure protein bands. The replicate bands
represents different preparation of proteins.
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After addition of isopropyl-1-thio-D-galactopyranoside (1.0 mM), the cultures
were incubated for 4 hours at room temperature. The cells were lysed using lysis
buffer [8 M urea (pH 8.0), 100 mM monosodium phosphate, 10 mM Tris Base].
Protein purification was carried out using an Ni2+ charged IMAC Select Affinity
Gel [Sigma-Aldrich] column for purification of His-tagged proteins. The column
was washed with wash buffer [20 mM imidazole (pH 8.0), 300 mM NaCl, and 50
mM monosodium phosphate]. The protein was eluted with elution buffer [300 mM
imidazole (pH 8.0), 300 mM NaCl, and 50 mM monosodium phosphate] and was
dialyzed in 20 mM Tris-HCl to remove extra salts and re-nature the protein.

3.3.4 In vitro IP using purified recombinant proteins
The Srx (2 µg) was incubated with multiple concentrations of Prx1wildtype and
Prx1mutant (500 ng, 1µg, 2 µg, 4µg) in 500 µL of IP buffer for 2 hours at 4o C. The
samples were incubated with anti-Srx antibody overnight at 4o C. Next morning
magnetic beads coated with anti-rabbit secondary antibody was incubated with
samples for 2 hours. The sample was separated using magnetic bars. The beads
were washed 3 times with fresh IP buffer. The protein was eluted using 1X LDS
buffer buy heating at 90o C for 10 minutes. The western blot were carried out
using standard procedures.

3.3.5 Study of the Srx-Prx interaction kinetics using surface plasmon
resonance (SPR)
The interaction of Srx (analyte) with Prx1wildtype and Prx1mutant (ligand) was
measured by surface plasmon resonance (SPR) technique using ProteOnTM
XPR36 instrument (Bio-Rad). The ligands were immobilized on GLC sensor
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chips (Bio-Rad) using the amine coupling method using BioRad standard
manufacturer protocol. Ligand capturing on the GLC chip was performed as per
the manufacturer’s protocol. Several different concentrations of pure recombinant
Srx (analyte) were used to evaluate the ligand-analyte binding. The data were
acquired and processed by ProteOn manager software and the Langmuir 1:1
evaluation model was used for analysis.

3.3.6 Statistical analysis
SPR data analyzed using the Langmuir 1:1 evaluation model. Quantitative data
were presented as mean ± standard deviation (x� ± SD). Data were analyzed with

the indicated statistical methods using SigmaPlot (version 13.0). For calculation
of the p-value, parameters of two-tailed 95% confidence interval were used for all
analyses (p ≤ 0.05 was considered statistically significant).

3.4 Results
3.4.1 Complete 3D-structure of full length proteins were predicted using
homology modeling
Multiple homology modeling programs were tested for prediction of dimeric
structure. Swissmodel predicted a partial structure, which we could not use for
our purpose. Phyre2 gave good results as well; however, I-TASSER proved to be
the best for all proteins under this study. Although I-TASSER is time consuming,
the capability of predicting the best structure from minimal information was
appreciable. Therefore, we determined the structure of Prx1 and Srx monomer
using I-TASSER (Figure 3-2). Prx1 monomers were uploaded to M-ZDOCK to
predict the structure of Prx1 dimer.
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Figure 3-2: Representative images of Srx and Prx1: The Srx binding site
forms a groove. Prx1 has a extending C-terminal arm of the Prx1 dimer.
Prx1mutant is prepared by deletion of the last 22 amino acids from the C-terminal
arm. The structure of (A) Srx (ribbon), (B) Srx (spheres), (C) Prx1 wild type
dimer, and (D) Prx1mutant dimer, are shown, with important cysteines marked in
red, other binding site amino acids marked in magenta, and the last 22 amino
acids of Prx1 marked in orange. Srx is marked in white and Prx chains are
marked in green
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We received multiple structures with different scores for each of our predictions.
A best guess for possible structures was made on the basis of the individual
scores as well as information available in the literature. Different software has
different score range that correlates with the confidence in structure. We
compared the individual score and selected best structure for our study. A similar
strategy was used to predict the 3-dimensional structures of Prx2-4. The
structures of other Prxs were similar to Prx1 with slight differences in orientation
of the C-terminal (Figure 3-3). We observed an extending C-terminal arm in Prx1
that covers the peroxidatic (CP) and resolving (CR) cysteine of Prx1 dimer (Figure
3-2C). Similar C-terminal arms are present in other Prxs with a slightly different
orientation (Figure 3-3). The 3-dimensional structure of Prx1mutant (Figure 3-2D)
was predicted by deleting the 22 amino acids from the C-terminal of both chains
of the Prx1 dimer.
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Figure 3-3: Representative images of typical 2-Cys Prxs other than Prx1: Full length structures of (A) Prx2
dimer, (B) Prx3 dimer, and (C) Prx4 dimer, produced by homology modeling. All important cysteines are marked in
red, the last 22 amino acids of Prx are marked in orange, and the rest of the Prx chain amino acids are marked in
green

3.4.2 Protein-protein docking output identified a possibility of steric
hindrance for the Srx-Prx interaction
All protein-protein docking studies were carried out using the ZDOCK online
server. The hydrophobic pocket of Srx along with CP and CR of Prxs were defined
as the binding site [55]. Docking output was visualized using the PyMOL
visualizer. The results of docking indicated that the extending arm of Prx1 might
create some steric hindrance for access of Srx to Prx1 (Figure 3-4A) as this arm
covers the part of Prx1 that needs to be accessed by Srx for Prx1 reduction.
Comparison of this phenomenon with Srx binding to other typical 2-Cys Prx
indicated the possibility of steric hindrance in these Prx as well. However, the
extent of hindrance may vary due to orientation of the C-terminal arm in an
individual Prx. This may lead to differences in interaction affinity of Srx for
individual members of the typical 2-Cys Prx family. Deletion of the C-terminal arm
might reduce this steric hindrance (e.g. Srx may have easier access to Prx1mutant)
(Figure 3-4B). Hence, deletion mutation may result in faster interaction between
Srx and Prx.

3.4.3 IP assay confirms the differences in interaction of Srx with individual
Prx
The pull-down assay indicated differences in interaction between Srx and
individual Prxs under normal and oxidative stress conditions. A multiple-fold
increase exists in pull-down of Prx3 and Prx-SO3 under oxidative stress
conditions whereas the difference is less obvious in cases of Prx1, Prx2 and Prx4
(Figure 3-5A & B). It could be due to mitochondrial location of Prx3. Srx cannot
translocate to mitochondria under non-stress conditions.
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Figure 3-4: The C-terminal arm hinders Srx binding to Prx1: Structures of Srx bound to (A) Prx1wildtype dimer
and (B) Prx1mutant dimer, with highlighted Srx binding site (magenta), Prx cysteine (red) and the last 22 amino acids
of Prx (orange) to depict the ease of access of Srx binding site to CP of Prx1.
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Figure 3-5: Effect of H2O2 treatment on Srx interaction with various typical 2-Cys Prxs in HEK293T cells: (A)
Western blot showing the relative amount of individual Prxs and oxidized Prx pulled down under oxidative stress
conditions induced by 10 min treatment with 500 µM and 1000 µM H2O2 compared to non-treated control; (B) band
strength of individual Prxs under oxidative stress conditions compared to non-treated control as quantitated by ImageJ
software. All bands shows same western blot gel. Quantitation is done for 4 different films. The quantitative comparison
was carried out using One-way ANOVA followed by Holm-Sidak post-hoc analysis.

Under oxidative stress conditions, the mitochondrial wall’s permeability increases
leading to Srx translocation to mitochondria and hence, increased Srx-Prx3
interaction. Increased Prx-SO3 is mainly due to increased oxidation of Prx under
oxidative stress conditions. The C-terminal arm of Prx is known to re-orient itself
once the Prx is oxidized [54]. These conformational changes can explain the
differences in Srx-Prx interaction under different redox states. The difference in
interaction of Prx3 may be partially due to its localization in the mitochondrial
compartment where Srx cannot reach under normal culture conditions. However,
no such factor plays a role in the case of Prx1, Prx2 and Prx4. Hence,
differences in interaction of these Prxs to Srx under oxidative stress conditions
could be attributed to molecular rearrangements in these Prxs. The difference
between Srx interactions and individual Prxs may be partially due to the different
orientation of the C-terminal arm in these Prxs, as predicted by homology
modeling. However, these differences need to be confirmed by further evidence.
3.4.4 Srx binds more efficiently to Prx1mutant than Prx1wildtype
IP, which was carried out using recombinant Srx, Prx1wildtype and Prx1mutant,
indicated the effect of the C-terminal arm on the Srx-Prx interaction. When equal
amounts of Prx1wildtype and Prx1mutant were incubated with a fixed amount of Srx,
more Prx1mutant was pulled-down by IP using anti-Srx antibody compared to
Prx1wildtype (Figure 3-6A & B). The differences in binding are not as obvious at
lower Prx concentrations since at such concentrations excess of Srx is available
for each molecule of Prx1wildtype and Prx1mutant. Hence, differences in binding are
compensated by the excess of Srx.
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Figure 3-6: Prx C-terminal arm deletion enhances the Srx-Prx interaction: For the same amount of Prx1 wild type and
mutant incubated with a fixed amount of Srx, more Prx1mutant is pulled-down along with Srx compared to Prx1wildtype. (A)
Western blot showing amount of Prx1wildtype and Prx1mutant pulled down along with Srx; (B) quantitated values of Prx1widltype
and Prx1mutant pulled down at each concentration of Prx1. The quantitation represents bands from 4 different films. The
positive (+ve) control contains only Srx, with no Prx. The negative (-ve) control contains only Prx1 wildtype or mutant, but
no Srx.

The differences become quite obvious at higher Prx1 concentrations. As the Srx
concentration becomes a limiting factor for interaction, a greater fraction of Prx
with higher affinity (i.e. Prx1mutant) for Srx is pulled-down with anti-Srx antibody.
These results confirm that Prx1mutant has higher steady-state interaction potential
for Srx compared to Prx1wildtype. The results also emphasize the possibility that
the C-terminal arm of Prx1 may cause some steric hindrance for Srx-Prx1
interaction.

3.4.5 Deletion of Prx C-terminal arm leads to faster Srx-Prx association with
minimal effect on dissociation
The effect of C-terminal arm deletion on kinetics of the Srx-Prx interaction was
studied using the SPR technique. The deletion mutation resulted in more than a
1,000-fold increase in association rate constant (ka) of the Srx-Prx1 interaction
i.e. at equivalent molar concentrations of Prx1wildtype and Prx1mutant, the ka for the
Srx-Prx1mutant interaction was more than 1,000-fold higher compared to ka for the
Srx-Prx1wildtype interaction (Table 3-1; Figure 3-7 A & B). However, the deletion
mutation did not significantly affect the dissociation rate constant (kd). Overall, the
deletion mutation resulted in more than a 1,000-fold increase in interaction
affinity. Based on homology modeling, we predicted slight differences in the
orientation of the C-terminal arm in different Prx. Our predictions indicated that
the C-terminal may cause steric hindrance to Srx access in all typical 2-Cys Prxs.
However, the extent of steric hindrance could be different. To confirm our
hypothesis, we deleted the same sequence of 22 amino acids from Prx4 and
studied the interaction kinetics.
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Table 3-1: The C-terminal deletion of Prx1 increases its affinity for Srx : The kinetic parameters calculated using SPR
indicates faster rate of association and higher affinity of Srx for Prx1mutant compared to Prx1wildtype. E represents value of
10. ka is association rate constant. kd is dissociation rate constant. KD is equilibrium dissociation constant. KD has inverse
relationship with affinity of interaction.

Parameters (Unit)

ka (1/Ms)

kd (1/s)

KD (M)

Comments
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wildtype

Prx1

Prx1mutant
(last 22 amino acids
from Prx1 C-terminal
are deleted)
Prx4wildtype
Prx4mutant
(last 22 amino acids
from Prx1 C-terminal
are deleted)

-01

6.93 E

+03

2.54 E

5.32 E

-04

4.44 E

-01

5.09 E

+01

9.04 E

-04

-03

1.66 E

-03

2.69 E

-04

7.69 E

-07

1.75 E

-03

3.26 E

-05

2.97 E

Prx1 has a slow rate of association but a very slow rate
of dissociation. It results in a longer time required to form
the Srx-Prx interaction but is a highly stable complex.
Deletion mutation results in more than 1,000-fold
increase in rate of association with minimal effect on rate
of dissociation.
Compared to Prx1wildtype, the Srx-Prx4 complex
dissociates faster.
Deletion mutation results in more than 100-fold increase
in rate of association with minimal effect on rate of
dissociation.
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Figure 3-7: C-terminal deletion mutation increases the Srx-Prx affinity: The kinetic parameters calculated using SPR
indicate a slower rate of association and lower affinity of Srx for (A) Prx1wildtype compared to (B) Prx1mutant as well as (C)
Prx4wildtype compared to (D) Prx4mutant. Different color lines represent different concentrations of analyte. The dissociation
rate is calculated from the peak of each curve i.e. the time we stop influx of protein for association. Hence, association
and dissociation are measured at different times. Hence, two parameters are independent of each other.

Again the SPR analysis confirmed our hypothesis. Deletion of the C-terminal arm
in Prx4 resulted in more than 100-fold faster association (ka) with minimal effect
on dissociation (kd) (Table 3-1; Figure 3-7 C & D). Hence, both Prx1 and Prx4
deletion mutations confirm our hypothesis about the steric hindrance caused by
Prx C-terminal site for Srx access to Prx. There is lower effect of Prx4 C-terminal
deletion on Srx-Prx4 interaction, compared to effect of Prx1 C-terminal arm
deletion on Srx-Prx1 interaction.

3.5 Discussion
Proteomics is one of the fastest evolving fields in molecular biology. The
molecular interaction of individual proteins can regulate a variety of cell signaling
processes elucidating their role in physiological homeostasis as well as
pathological conditions. The importance of these macromolecules has led to
development of various tools that can provide insight from their molecular
structure. Multiple experimental methods are available to study the structure of
proteins; however, these methods have limitations in maintaining the
conformation of a native protein in an environment suitable for structural
prediction by nuclear magnetic resonance or X-ray crystallography. It takes years
of research by a group of structural chemists to determine the structure of a
simple protein. Often, these research efforts are insufficient to predict the
complete structure of proteins.
The time and effort required for structural predictions using experimental
methods and the limitations of these methods led to development of
computational tools that can help structural chemists to temporarily fill the gap in
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existing knowledge. Homology modeling is a computational method of protein
structural prediction that provides great potential to fill the gap in existing data
within acceptable limits of error [160]. Protein-protein docking is another
computational method that provides insight into protein functions and molecular
characteristics by filling the gap in existing knowledge about protein-protein
interactions [161]. Both of these techniques are used in this study to help us
understand the Srx-Prx interaction. A great amount of biochemical data related to
Srx-Prx interaction is already available. We utilized experimental and
computational prediction data to make a hypothesis that the C-terminal arm of
typical 2-Cys Prxs may cause steric hindrance for the Srx-Prx interaction, as
depicted in Figure 3-8. Experimental evidence from the existing literature
suggests similar interaction of Srx with all 4 typical 2-Cys Prx. However, by virtue
of being different proteins of the same subfamily, they also have minor
differences in their characteristics. Our computational prediction indicated that
those minor differences in interaction may be due to varying orientations of the
C-terminal arm of Prx. To confirm our prediction of steric hindrance and the role
of the Prx C-terminal arm in Srx-Prx interaction, we performed deletion mutation.
Due to similarities in typical 2-Cys Prx and accepted conventions in the field, we
decided to first study Prx1 molecular characteristics. The research in this field
clearly establishes that differences in biochemistry of Srx interaction with
individual typical 2-Cys Prx are minor. The major differences between typical 2Cys Prx come from their subcellular localization, not their molecular
characteristics [30]. The Prx C-terminal arm contains 26 amino acids.
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Figure 3-8: Extending C-terminal arm of Prx covers the Srx-Prx interface and may cause steric hindrance for Srx
access to Prx: The figure depicts the relative location of the Prx C-terminal extending arm and location where the
concave shape of the Srx-hydrophobic pocket needs to fit to carry out Prx reduction. In the presence of the C-terminal
arm, Srx can access the Prx binding site only from a unique direction, leading to steric hindrance for Srx interaction. In
absence of a C-terminal arm, Srx is freer to access Srx from different directions, which may result in faster association.
The importance of inhibition of this interaction and its evolutionary values are mentioned in chapter 1 of this dissertation.

Out of those, the initial 4 amino acids are critical for Prx antioxidant function,
while the last 22 amino acids do not affect the Prx antioxidant function. Hence,
we deleted the last 22 amino acids of Prx1 C-terminal and studied its effect on
Srx-Prx interaction. The effect of deletion mutation was studied on both steadystate Srx-Prx interaction and kinetics of the Srx-Prx interaction. The IP
experiments indicated that the deletion mutation enhances the steady-state SrxPrx interaction. It was not clear whether the effect on steady state interaction was
due to changes in rate of association or dissociation or both. SPR is the
technique of choice to study kinetics of protein-protein interaction [162]. This
technique was used for studying the effect of C-terminal deletion on the kinetics
of the Srx-Prx interaction. The SPR results indicated more than 1,000-fold
increase in the association rate constant (ka) after deletion of the C-terminal arm.
Higher ka is a direct indicator of faster rate of association. Hence, C-terminal arm
deletion leads to approximately 1000-fold faster rate of association. The deletion
mutation resulted in a slight reduction in dissociation rate constant (kd). The ratio
of kd/ka is equal to the equilibrium dissociation rate constant (KD) in SPR. The
reciprocal of KD is an indicator of affinity. Hence, lower KD indicates better affinity
of the Srx-Prx interaction. Deletion mutation reduces the KD value of the Srx-Prx1
interaction by more than 1000-fold; hence, Prx1 C-terminal arm deletion results
in more than 1000-fold increase in affinity of the Srx-Prx1 interaction.
To further confirm the applicability of these results to other typical 2-Cys Prxs, the
effect of this same deletion mutation was studied in Prx4. Considering
differences in C-terminal arm orientation (as predicted from homology modeling),
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we expected that the extent of steric hindrance may be slightly different than
what we saw in Prx1. This prediction was confirmed by SPR analysis of Srx
interaction with Prx4wildtype and Prx4mutant. The deletion mutation in Prx4 resulted
in roughly 100-fold increase in ka with minimal effect on kd. Again, the equilibrium
dissociation constant (KD) for the Srx-Prx4mutant interaction was calculated to be
approximately 100 times lower than the KD for the Srx-Prx4wildtype interaction. The
effect of differences in orientation of the C-terminal arm indicated a 10-fold
difference in effect of C-terminal arm deletion (i.e. 1,000-fold in the case of Prx1
while only 100-fold in the case of Prx4). Hence, deletion of the C-terminal arm of
Prx affects the rate of Srx-Prx association and these results can be extrapolated
to other typical 2-Cys Prx. However, the extent of the effect may be different in
other typical 2-Cys Prx.
While considering structural details of the Srx-Prx interaction published by
Jonsson and colleagues, we found supportive evidence to our hypothesis [163].
The YF (tyrosine-phenylalanine) motif present in the C-terminal arm of Prx
actually occludes the Srx-Prx interaction [163]. The YF motif is responsible for
holding the C-terminal arm in a particular orientation, where it causes steric
hindrance for the Srx-Prx interaction resulting in reduced rate of association.
Jonsson and colleagues, also states a slight stabilizing effect of the C-terminal
arm on the Srx-Prx complex. However, our data indicates very low effect of Cterminal arm deletion on dissociation rate constant (kd). We repeated these
experiments 5 times and found very low effect on kd in each repetition, wherease
the effect on ka was always multifold. On comparison of experimental methods,
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we found that the Jonsson group used an N-terminal truncated Srx (amino acid
1-37 deleted) for their study, while we used the complete Srx sequence. The
differences in the Srx-Prx complex stability (once it is formed) can be partially
due to the presence of N-terminal in our protein which is present at the site
where the Prx C-terminal arm wraps itself around Srx. Figure 3-9 shows
representative images of these differences. Hence, it can be concluded from
experimental data that the C-terminal arm of Prxs causes steric hindrance for Srx
association with Prxs. However, it may have a slight stabilizing effect on the
formed complex. Such a stabilizing effect should be minor compared to the multifold effect of Prx C-terminal on rate of association and it may have a minor effect
on overall affinity. Taken together, these results give us some insight about the
molecular characteristics of Srx-Prx interaction. Hence, this information about the
Srx-Prx interaction interface can help us in successfully designing targeting
strategies to inhibit the Srx-Prx interaction.
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Figure 3-9: The Srx-Prx complex showing crystal structure with truncated Srx N-terminal: (A & B) The
complete Srx structure predicted via homology modeling with N-terminal amino acids 1-37 marked yellow to
represent the truncated part (C & D) and its orientation.

3.6 Summary
Srx hydrophobic pocket formed by the Srx active site binds with a Prx homodimer
in a region where CP and CR of alternate monomers is located. The C-terminal of
the second monomer (the one with CR in the binding site) covers the binding site
and forms a pocket. This C-terminal arm can cause steric hindrance for Srx
access to Prxs. Our data confirms this steric hindrance as deletion of the Cterminal arm results in increased steady state interaction between Srx and Prxs.
Hence, Prx C-terminal arm is not required for Srx-Prx interaction. This data is
further confirmed by kinetic studies which indicate that deletion mutation results
in much faster association of Prxs with Srx with very low effect on dissociation. It
results in overall higher affinity of the Srx-Prx interaction. Taken together, this
study adds insight to the molecular characteristics of the Srx-Prx interaction and
may help us design future targeting strategies for inhibition of the Srx-Prx
interaction.
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CHAPTER 4: TARGETING SRX-PRX INTERACTION USING
SMALL-MOLECULE INHIBITORS
4.1 Synopsis
The Srx-Prx axis is a critical component of the antioxidant system in eukaryotes.
It is involved in pathogenesis of various oxidative stress-induced conditions that
includes (but is not limited to) lung, skin, and colorectal cancer. The purpose of
this study is to target the Srx-Prx interaction using small molecules that may
further lead to development of novel therapeutics. We used in silico virtual
screening and protein-small molecule docking to identify a few inhibitors of SrxPrx interaction. Multiple in silico parameters were used as filters to minimize the
number of small molecules to be tested. Molecules shortlisted on the basis of
computational predictions were tested using in vitro techniques. These chemicals
significantly reduced the chances of cell growth. ISO1 was found to be the best
Srx inhibitor, with a KD of 42 nM. Taken together, these data show a promising
approach to identifying an Srx inhibitor that can be employed as a research tool
as well as a therapeutic tool in the future.
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4.2 Introduction
Macromolecular protein-protein interaction plays a very important role in several
cell-signaling pathways, including redox signaling [164]. Srx-Prx interaction is
one example of intracellular protein-protein interaction involved in redox
signaling. Protein-protein interaction is one of the most complex macromolecular
interactions inside cells and scientists have devoted decades of research to
inhibit such interaction using small molecules [165]. Identification of a proper
targeting strategy and target site is the most daunting task in the drug-discovery
process. Decades of research from computational biologists have led to
development of in silico tools that can be used to identify pockets or target sites
in individual proteins that can be targeted using small molecules [166]. Molecular
biologists can contribute to identification of proper targeting sites by identifying
amino acids essential for protein function. In fact, contribution of molecular and
computational biologists must complement each other for successful drugdiscovery. Virtual screening is the process of screening a ligand library against a
given target site or well-defined pocket or entire 3-dimensional structure of a
given protein [167]. Virtual screening has proved to be a good computer-aided
drug-designing tool in recent years as it helps to reduce the cost and time
required for drug discovery. Virtual screening is a daunting task as identification
of target sites and orientation of molecules that may lead to inhibition of a protein
are still based on individual judgment of the researcher. Knowledge of molecular
biology, and especially the molecular characteristics of particular protein-protein
interaction, can prove to be a great asset for computational biologists as it helps
to improve the accuracy of predictions and probability of success in later stages
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of the drug-discovery process. Hits selected by virtual screening can either
undergo further in silico screening for their pharmacokinetic properties or can be
directly subjected to in vitro testing. The path taken for hits is selected based on
availability of resources and prospective use of the molecules.
Molecular biology research reported in earlier chapters of this dissertation helped
us identify a prospective pocket in typical 2-Cys Prxs. The amino acids of Srx
that are involved in Srx-Prx interaction have been documented in the literature
[127]. The amino acids form a groove/pocket in the Srx structure that can
potentially be targeted by small molecules. The probability of small molecule
binding sites can be predicted using pocket finder software, such as ConCavity
and MetaPocket 2.0 [168, 169]. We used the aforementioned pockets of Srx and
Prx for a virtual screening process. Screening 8,836,468 chemicals available in
the ZINC online database against our targets returned 1,400 hits. We filtered
these hits based on predicted pharmacokinetics and pharmacodynamics and
shortlisted 100 molecules. Due to lack of funding, we decided to test only 4
molecules. I selected 4 molecules that covered 4 different chemical classes. One
of them showed promising results. We named it inhibitor of sulfiredoxin
oxidoreductase 1 (ISO1). ISO1 showed good efficacy against Srx. However, its
pharmacokinetic profile needed improvement. ISO1 is an amphoteric molecule
with lipophilicity outweighing hydrophilicity. Hence, we tested 3 more molecules
while looking for a molecule with better pharmacokinetic profile. The main
purpose of testing these molecules was to find an efficacious molecule with
better pharmacokinetic profile. We finally tested these chemicals in vitro, using
87

lung cancer cell lines. As an aside, we later collaborated with the University of
Kentucky College of Pharmacy for screening of more chemical libraries against
the given target sites in Srx. We identified 41 more molecules with the help of Dr.
Zhan’s laboratory and these are being tested in vitro; however, those molecules
are not part of this dissertation and their testing will be continued in the future.
Virtual screening and in vitro testing helped us identify the molecule that shows
the most promising inhibition of cancer cell growth at minimal toxicity to normal
organ control cells. It may be beneficial for future research to use QSAR
techniques to design and test new molecules related to the one identified in our
study, as this will help in identifying molecules with better efficacy and lower
toxicity potential.

4.3 Materials and methods
4.3.1 Cell lines, plasmids, antibodies and chemicals
Human lung cancer A549 cells were obtained from ATCC and cultured in RPMI
medium containing 10% fetal bovine serum under standard conditions. All
experiments were performed using cells within 10 passages from resuscitation.
Primary antibodies used include rabbit

anti-Srx (Proteintech, Chicago, IL;

Catalog 14273-1-AP), rabbit anti-Prx I (Abcam, Cambridge, MA; Catalog
ab41906), rabbit anti-PrxSO3 (Abcam Catalog ab16830), mouse anti-β-actin
(Sigma–Aldrich; Catalog A2228), mouse anti-Prx III (Santa Cruz Biotech; Catalog
SC-59661), anti-pERK (Cell Signaling, Billerica, MA; Catalog 9101S), anti-ERK
(Cell Signaling, Billerica, MA; Catalog 4376S), anti-p-c-Jun (Cell Signaling,
Billerica, MA; Catalog 9261L), anti-c-Jun (Santa Cruz; Catalog SC-1694), anti88

pCREB (Cell Signaling, Billerica, MA; Catalog 9198S), and anti-CREB (Cell
Signaling, Billerica, MA; Catalog 9197). Recombinant human EGF was
commercially obtained (Sigma-Aldrich). All the molecules tested in vitro were
purchased from eMolecules (La Jolla, CA) or other registered vendors on the
ZINC database. Molecules from other chemical libraries were provided by the
University Of Kentucky College Of Pharmacy. Dimethyl sulfoxide (DMSO) was
purchased from Alfa Aesar (Ward Hill, Massachusetts).

4.3.2 Virtual screening to identify the Srx-Prx interaction inhibitor
Binding pockets were predicted based on previous experiments mentioned in this
dissertation as well as existing literature [54, 55]. Those binding pockets were
further confirmed using ConCavity and MetaPocket 2.0 software. We screened
approximately 8.8 million compounds from the ZINC database [170] using DOCK
Blaster (an online server) [171] against Srx. Out of these compounds we
identified approximately 1,400 that can bind to Srx in different orientations. We
used iGEMDOCK as a second virtual screening software for confirming the
output of DOCK Blaster [172]. We selected these molecules and further
predicted their metabolic profile using MetaPrint2D-React (online server) [173].
We used multiple filters to further minimize the number of compounds to be
tested. The filters are listed in Table 4-1 with their significance in the drug
discovery process. After incorporating these filters, we still had approximately
100 compounds that could be tested in vitro; however, we tested 7 of them based
on chemical class and individual filters.
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Table 4-1: Filters applied to shortlist virtually screened hits and their significance
Significance in Drug Discovery Process

Binding site

Overall probability of inhibition

Binding energy

Probability of competitive inhibition

Number of contacts

Increases the probability that the aforementioned parameters will be fulfilled

Lipinski’s Rule of Five

Drug-likeness

Metabolites

Pharmacokinetics as well as pharmacodynamics

Chemical class

Rough idea about other difficulties that may arise during testing of molecules

Toxicity

May limit pre-clinical/clinical outcomes
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Filter

4.3.3 Small molecule assay for Srx inhibitory activity
A549 cells were pre-treated with 20 µM of the individual compounds being tested
for 45 min followed by treatment with H2O2 for 10 min. The treatment groups
were incubated with 20 µM individual Srx inhibitor for another 4-6 hour. The
DMSO treated group was used as recovery control, a 0-hour H2O2 treated group
was used as oxidation control, while a non-treated group was used as basal level
oxidation control.

4.3.4 Western blotting, IP, and phosphokinase profiling
Earlier data from our group has shown that Srx enhances phosphokinase
signaling [32]. Western blotting and IP were performed using standard protocols.
Whole cell lysate as well as purified recombinant proteins (purified as per
protocol in Chapter 3) were used for IP. According to affinity of the antibodies
and protein molecular weight, membranes were cut and stripped for multiple
western blots to minimize variation. All cells were cultured in T75 flasks, cells
were collected by trypsinization, and cell numbers were counted in a Coulter cell
counter. Cells were then lysed in RIPA buffer at a concentration of 2 × 107
cells/mL. For phosphokinase profiling, cells were serum starved for 18-20 hours
along with 20 µM chemical inhibitor. After serum starvation, we added serumcontaining medium along with100 ng/mL EGF. The cells were incubated with
EGF containing media for multiple different time-points. Cells were then lysed in
RIPA buffer and western blot was performed to study phosphokinase signaling.
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4.3.5 Colony formation, cell proliferation assay and cell cycle analysis
For the colony formation experiment, cells were suspended in 0.3% agar and
2,000 cells/well were seeded into a 24-well plate pre-coated with 0.5 ml of 0.6%
agar. Culture medium was changed every 5 days for 4 weeks. The number and
size of colonies were examined and data were obtained by analyzing with
OpenCFU software. For the cell proliferation assay, 2,000 cells were plated per
well of a 24-well plate. The chemicals were added the next day. The medium was
changed every 24 hours with fresh media and inhibitor added at each time-point.
After 72 hours, cells from each well were trypsinized and suspended in 1 mL
media. The number of cells was counted 3 times with Coulter counter. To study
the effect of Srx inhibition on cell cycle, we used flow cytometry analysis. An
equal number of A549 (lung adenocarcinoma) cells were plated in 100 mm
dishes. The next day, we started serum starvation with media free of any serum.
After 24 hours serum starvation, we added fresh media containing 10% serum
and 20 µM ISO1. The cells were incubated for another 24 hours with inhibitor and
serum containing media. Finally, cells were trypzinized and stained using
propidium iodide. Cell cycle analysis was carried out using standard protocol at
the University of Kentucky College of Medicine facility for Flow Cytometry. 10,000
cells were counted for each treatment group.

4.3.6 Surface plasmon resonance study of Srx-Prx interaction kinetics
The interaction kinetics of Srx (ligand) with chemical inhibitors was measured by
SPR technique using ProteOnTM XPR36 instrument (Bio-Rad). Srx was
immobilized on GLH sensor chips (Bio-Rad) using the amine coupling method.
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Ligand capturing on the GLH chip was performed as per the manufacturer’s
protocol. Several different concentrations of pure chemical inhibitors were used
to evaluate the ligand-analyte binding. The data were acquired and processed by
ProteOn manager software and Langmuir 1:1 evaluation model was used for
kinetic analysis.

4.3.7 Wound healing assay
To test the effect of ISO1 on wound healing, cells were seeded in 6-well plates at
a density of 1 × 106 cells per well to reach faster confluence. Wounds were made
by scratching with a sterile 1000 μL pipette tip. Floating cells were removed by
rinsing three times with PBS. Images of cell migration at different time points
were recorded using the microscopic camera and AmScope 3.7 software.

4.3.8 Statistical analysis
SPR data was analyzed using the Langmuir 1:1 evaluation model. Quantitative
data were presented as mean ± standard deviation (x� ± SD). Data were analyzed

with indicated statistical methods by using SigmaPlot (version 13.0). For
calculation of the p-value, parameters of two-tailed 95% confidence interval were
used for all analyses. P ≤ 0.05 was considered statistically significant.

4.4 Results
4.4.1 Srx contains a good druggable pocket suitable for virtual screening
Identifying a drug target site is a cumbersome step in the drug discovery process.
We predicted a prospective target site in Srx and Prx using data from Chapter 3
of this dissertation as well as from existing literature [54, 55]. However,
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druggability of these sites needed to be confirmed. First, we predicted possible
small molecule binding sites in Srx and Prx1 homodimers (as a representative of
typical 2-Cys Prx subfamily) using MetaPocket 2.0 open access software (Figure
4-1A&B), which predicts 3 possible target sites in each protein. The target sites
that were predicted based on experimental data were confirmed by MetaPocket
2.0 prediction. To further confirm druggability of these target sites, we predicted
druggable pocket(s) using ConCavity open access software (Figure 4-1C&D).
ConCavity predicted a druggable pocket in sulfiredoxin that covers the target
sites predicted based on experimental studies as well as one of the target sites
predicted by MetaPocket 2.0 software. However, ConCavity failed to predict a
druggable pocket in the Prx1 homodimer. Confirmation of the druggability of the
Srx pocket by multiple approaches increased the chances of accurate prediction
as a target site; hence we further pursued this target site during in silico
screening.

4.4.2 In silico studies led to selection of four chemicals for in vitro testing
Based on earlier experimental results and in silico predictions, we defined
multiple target sites of Srx and carried out virtual screening using DOCK Blaster.
The output of DOCK Blaster was confirmed by iGEMDOCK. Based on two virtual
screening methods we identified 1,400 hits. To further refine the list of molecules,
we used multiple filters defined in Table 4-1. We shortlisted 100 molecules based
on advanced filtration. Due to economic constraints, we could not test many
molecules. Hence, we first selected 4 molecules from 4 different chemical
classes with the best predicted results on the basis of individual filters.
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Figure 4-1: Predicted pockets in Srx and Prx1: MetaPocket 2.0 predicted 3 probable binding pockets in Srx (A)
and Prx1 (B); ConCavity predicted one pocket in Srx (C & D) as a druggable target but it could not confirm the
presence of a druggable pocket in Prx1.

The 4 chemicals with selected parameters are listed in Table 4-2, and
representative images of the Srx-binding site are shown in Figure 4-2. Based on
in vitro results, we carried out quantitative structure-activity relationship (QSAR)
predictions to identify more molecules related to ISO1 while trying to identify an
inhibitor with better pharmacokinetic profile. We tested 3 more chemicals related
to ISO1 but none of them produced better effect. Hence, the majority of in vitro
results reported in this chapter belong to ISO1.

4.4.3 Two molecules showed inhibition of Srx activity
First we tested all small molecules for Srx inhibitory activity. We over-oxidized the
Prx in A549 cells and replenished the media with fresh media containing inhibitor.
We allowed the cells to recover for 4-6 hours in the presence of inhibitor.
ZINC64002748 (Mol3) and ISO1 showed inhibition of Prx reduction (Figure 4-3).
We tested these two chemicals for the rest of the in vitro studies. We tested small
molecules for their potential to inhibit Srx-Prx1 interaction using recombinant
proteins and IP assay. Both chemicals inhibited pull-down of Prx1 with Srx at 100
µM concentration (Figure 4-4A & B). However, at lower concentrations, ISO1
showed better effect compared to ZINC64002748. To compare the intracellular
efficacy of these two molecules, we used HEK293T cells over-expressing FLAGSrx. On treatment with H2O2, followed by cell lysis using IP buffer containing 20
µM of small molecules, ISO1 successfully inhibited pull-down of Prx-SO3 (i.e.
over-oxidized form of Prx) with Srx (Figure 4-4 C & D). Hence, ISO1 can inhibit
Srx interaction with Prx in both reduced as well as oxidized state.
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Table 4-2: List of 4 chemicals selected on the basis of virtual screening
Parameter

ZINC38768782

ZINC39975876
N-(2,4dimethoxyphenyl)-2,3dioxo-quinoxaline-6carboxamide

ZINC 64002748
5-[2-[2furylmethyl(methyl)
amino]acetyl]benzimidaz
ol-2-one

ZINC 142037 (ISO1)
4-cyano-N-(3ethynylphenyl)
benzene-1sulfonamide

-49.82 kcal/mol

-81.76 kcal/mol

-103.22 kcal/mol

-70.13 kcal/mol

4

3

2

5

1.51

3.3

1.23

2.20

3

3

3

1

8

6

6

4

Mol1

Mol2

Mol3

ISO1

N-(4-isopropylphenyl)-2oxo-benzimidazole-5sulfonamide
Binding
energy
Number of
contacts

97

Sites of
metabolic
modifications
xLogP
H-bond
donors
H-bond
acceptors
Alternative
names used
in this
dissertation
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Figure 4-2: Representative images of docked small molecules in Srx-binding pocket.
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Figure 4-3: Effect of individual small molecules on Prx-SO3 reduction: ZINC64002748 and ISO1 inhibit Prx-SO3
reduction in A549 cells as evident from western blot and quantitative values of band in 4-hour (A & C) and 6-hour (B & D)
recovery.

Figure 4-4: Effect of ZINC64002748 and ISO1 on pull-down of Prx1 and PrxSO3 along with Srx: (A-B) Inhibition of Prx1 recombinant protein
immunoprecipitation with Srx recombinant protein; (C-D) Prx-SO3 IP along with
Srx in FLAG-Srx overexpressing HEK293T cells. Statistical method applied was
one-way ANOVA followed by Holm-Sidak post-hoc analysis (*p≤0.05). Upper
band in Prx-SO3 band represent Prx4-SO3 while other 3 Prx are part of lower
band.
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4.4.4 Two molecules inhibit cell growth and colony formation in lung and
colon cancer cells
On testing the effect of ZINC64002748 and ISO1 in lung cancer cell lines, we
found successful inhibition of non-small cell lung cancer (NSCLC) cell growth at
concentrations which showed minimal toxicity in non-cancer BEAS2B cell lines
from lungs (Figure 4-5 A & B). The effect was more selective for NSCLC cells
compared to small cell lung cancer (SCLC) cell lines i.e. H69 and H82 cells.
ZINC64002748 showed higher potency in A549 cells compared to ISO1. Similar
results were observed in the anchorage-independent cell growth (colony
formation)

assay.

Both

ISO1

and

ZINC64002748

inhibited

anchorage-

independent colony formation in the A549 NSCLC cell line. ZINC64002748
showed more potent inhibition of colony formation in A549 cells compared to
ISO1 treatment (Figure 4-6).

4.4.5 Surface plasmon resonance studies indicate higher affinity of Srx for
ZINC64002748 and ISO1 compared to Prx1
GLH chips were utilized to study the affinity of Srx for individual chemicals. Srx
was used as ligand while ZINC64002748 and ISO1 were used as analytes. On
calculation of kinetic parameters, we found both the chemicals showed higher
association rate constant (ka) for Srx compared to ka of Prx1 for Srx (Table 4-3;
Figure 4-7). On comparison of dissociation rate constant (kd), we found both the
chemicals have higher kd compared to Prx1. On comparison of equilibrium
dissociation rate constant (KD), we found that both the chemicals have lower KD
compared to Prx1 (Table 4-3). The kinetic parameters of Prx1 are calculated and
discussed in Chapter 3 of this dissertation.
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Figure 4-5: Effect of ZINC64002748 and ISO1 on cell growth: Small molecules
that inhibit Srx-expressing cell growth in lung cancer cells: (A) ISO1 and (B)
ZINC64002748. Each treatment was carried out in triplicates (n = 3).
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Figure 4-6: Small molecules inhibit anchorage-independent cell growth: (A)
Representative images of colonies; (B) concentration-dependent effect of ISO1
and ZINC64002748 on colony formation. Each treatment represents the
triplicates (n = 3).
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Figure 4-7: Surface plasmon resonance curves of Srx interaction with small
molecules: (A) ISO1 and (B) ZINC64002748. The faster on and off rate
represents micelle formation in case of ISO1 as shown in panel (A). It can also
occur due to multi-molecular binding to same protein molecule.
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Table 4-3: Srx has higher binding affinity for chemical inhibitors than Prx1 (SPR analysis): Srx-Prx1 kinetic
parameters were taken from Chapter 3 of this dissertation. The data represents a calculation carried out using 5 different
concentrations of analyte (small molecules).
Parameters (Unit)
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Ka (1/Ms)

Kd (1/s)

KD (M)

Comments

ISO1

8.65 E+07

3.61 E00

4.22 E-08

Srx has much higher affinity for ISO1 compared to
Srx affinity for Prx1 or ZINC64002748

ZINC64002748

2.08 E+02

1.86 E-02

8.95 E-05

Srx has slightly higher affinity for ZINC64002748
compared to Srx affinity for Prx1

Prx1

6.93 E-01

5.32 E-04

7.69 E-04

On comparison of KD values between the chemicals, we found ISO1 has a lower
KD (hence, higher affinity) for its interaction with Srx compared to ZINC64002748Srx interaction. The KD value for Srx-ISO1 interaction was 4.22 E-08 M (i.e. 42.2
nM) while that for Srx-ZINC64002748 interaction was 8.95 E-05 M (i.e. 89.5 µM).
These values are inversely proportional to the affinity of these molecules for Srx.
However, the EC50 in cell culture depends on variety of parameters including
uptake of these molecules by cells. As ISO1 is amphoteric in nature, it forms
micelles leading to hindered uptake into the cells. Hence, effect of ZIN64002748
is better in terms of EC50 compared to effect of ISO1.
4.4.6 ISO1 inhibits Srx-mediated phosphokinase signaling
Previous data from our lab indicates that Srx enhances phosphokinase signaling.
Knockdown of Srx results in reduced phosphokinase signaling. Hence, any Srx
inhibitor should produce effect similar to Srx knockdown on phosphokinase
signaling. To further confirm specificity of effects produced by two small
molecules, we tested their effects on phosphokinase signaling. ZINC64002748
indicated a slight stimulatory effect on phosphokinase signaling. However, Srx
inhibition should reduce the phosphokinase signaling. For individual time points,
ISO1 reduced the phosphokinase signaling at 20 µM concentrations (Figure 4-8).
The effect of ISO1 was similar to the one produced as a result of Srx knockdown.
Hence, all the effects produced by ISO1 add up to show its efficacy as a specific
Srx inhibitor. Even though ZINC64002748 showed higher potency against lung
and colon cancer cells, its effect may not be specific to Srx inhibition as it could
not consistently inhibit phosphokinase signaling as expected from a Srx inhibitor.
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Figure 4-8: ISO1 inhibits phosphokinase signaling: The western blot showing EGF-induced phosphokinase signaling
after (A) ZINC64002748 and (B) ISO1 treatment; the bands for individual time-points were quantitated using ImageJ
software and plotted as shown (C) 15 min, (D) 30 min, (E) 60 min, and (F) 120 min.

Hence, ZINC64002748 may not be a specific inhibitor of Srx. Considering
specificity of ISO1; we carried out the rest of the in vitro studies with ISO1.

4.4.7 ISO1 arrests cell growth in G2 phase
To confirm the effect of Srx inhibitor ISO1 on cell cycle phase, we used flow
cytometry. On testing the effect of ISO1 in lung cancer cells (A549), we found
substantial reduction in number of cells in the S-phase of cell growth (Figure 49A). The number of cells in G2 phase was higher compared to non-treated
control.

4.4.8 ISO1 inhibits cell-migration in wound healing assay
Earlier research from our lab shows that Srx enhances cell-migration in wound
healing assay [32]. To further confirm the specificity of ISO1, we tested its effect
on A549 cell-migration using wound healing assay. The wound was made by
scratching with a micropipette tip and cells were incubated with multiple
concentrations of ISO1. The ISO1 inhibited wound healing in a dose-dependent
manner (Figure 4-9B) with statistically significant inhibition obtained at
concentrations above 20 µM (p≤0.05).
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Figure 4-9: ISO1 inhibits lung cancer cell growth and migration: ISO1 (A)
inhibits cell cycle progression to S-phase; (B) inhibits cell migration in wound
healing assay.
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4.5 Discussion
Homology modeling and protein-protein docking studies reported in Chapter 3
along with existing literature helped us to identify the Srx-Prx interaction
interface. This interface could be targeted via amino acids in the Srx or Prx chain
that are present at interface or via dual binders that can act on amino acids at
both the Srx and Prx interfaces. Srx has three different sites that can be targeted
for inhibition of its enzymatic activity. Those sites include: (1) hydrophobic pocket
(i.e. a groove with multiple hydrophobic amino acids); (2) the ATP and Mg2+
cofactor binding site; and (3) Cys99 and neighboring amino acids [54, 55, 163].
The hydrophobic pocket is involved in Srx-Prx binding. ATP hydrolysis is
necessary for reduction of Prx-SO3 and Mg2+ acts as a cofactor in this process.
Cys99 is involved in formation of thiosulfinate intermediate, which is required for
reduction of Prx-SO3 but it is not important for the Srx-Prx binding [24]. Targeting
the ATP binding site has good potential to inhibit Srx and this site is easily
accessible to small molecules. However, the probability of toxicity was predicted
to be very high for any molecule that could bind at the ATP binding site.
Therefore, we did not test any of these molecules. Cys99 is also easily accessible
for small molecules. However, an effort to define Cys99 and only its adjacent
amino acids led to a huge number of hits during virtual screening. The chances
of non-specificity of interaction were very high in those molecules. The
hydrophobic pocket is an easily accessible groove with well-defined 3dimensional structure. This groove is responsible for Srx-Prx binding. Cys99 is
also present in proximity (but not inside) of this pocket. Hence, it may be a site of
interaction for a specific inhibitor. To reduce the number of false positive
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molecules in virtual screening, we defined a complex 3-dimesional target site that
included all important amino acid components of the hydrophobic pocket (Pro52,
Leu82, Phe96, Val118, Val127 and Tyr128) along with Cys99. Proximity of these amino
acids to each other made me believe that it would be a druggable target site.
However, druggability of a protein intramolecular target site can be affected by
myriad biochemical and structural factors. Therefore, I decided to confirm it with
two existing druggable pocket prediction tools: MetaPocket 2.0 and ConCavity.
The druggability of the pocket defined in this study was confirmed by both
in silico prediction methods. Based on existing literature and earlier experiments,
we had defined a pocket in the Prx dimer as a target site. However, the Prx
binding pocket druggability could not be confirmed using all methods.
Considering the narrower Prx pocket and inability to confirm its druggability by
prediction method, the chances of false positive in virtual screening was
predicted to be high.
Virtual screening is not a 100% accurate method and human judgment must be
used to improve the chances of success and minimize the numbers of false
positive as well as false negative. To reduce the chances of failure, we decided
to confine ourselves to virtual screening against the Srx pocket and use Prx
interface only for guidance. Virtual screening using DOCK Blaster and
iGEMDOCK helped us select 1,400 hits out of 8,836,468 molecules that were
originally screened against Srx. To minimize the number of false positives, we
utilized multiple filters related to pharmacokinetic and pharmacodynamic
descriptors. The filters allowed us to reduce the number to 100 chemicals. I
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refined the methodology and filters to select 4 compounds from 4 different
chemical classes. These molecules had the highest predicted probability of
success based on docking and molecular descriptors. The 4 chemicals were first
tested for their ability to inhibit the reduction of over-oxidized Prx. ZINC64002748
and ISO1 showed acceptable inhibition at 20 µM concentrations. Hence, both
were selected for further in vitro testing in cell culture. We later carried out a
QSAR study to improve the pharmacokinetic profile of ISO1 and selected 3
molecules for further testing. However, changes in structure that led to better
pharmacokinetic profile resulted in loss of anti-Srx activity. Hence, the majority of
data reported here are results of ISO1 testing in cell culture.
The chemicals were first tested for their ability to inhibit Srx by testing inhibition of
Prx-SO3 reduction. Oxidative stress resulted in hyperoxidation of Prxs. A 5-hour
recovery after induction of oxidation is sufficient for reduction of the majority of
Prx-SO3. Hence, the A549 cells were first treated for 10 minutes with H2O2, and
then were allowed to recover for 5 hours with fresh media containing different
concentrations of small molecules. The 0-hour oxidation control and DMSO
(vehicle) reduction control groups were used as controls for induction of oxidation
and recovery. Both ZINC64002748 and ISO1 showed successful inhibition of
Prx-SO3 reduction; however, the effect was more promising for ISO1. We next
tested the ability of these chemicals to inhibit the Srx-Prx and Srx-PrxSO3
interaction using pull-down assay. Both molecules inhibited the Srx-Prx
interaction at higher concentrations. However, at lower concentrations only ISO1
could significantly reduce the Prx pull-down along with Srx. Similarly, ISO1
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successfully inhibited Prx-SO3 pull-down along with Srx at 20 µM concentration
while ZINC64002748 could not produce significant effect on Prx-SO3 pull-down.
As mentioned earlier, the hydrophobic pocket of Srx is responsible for Srx-Prx
binding while Cys99 (amino acid outside hydrophobic pocket) is responsible for
enzymatic activity. Hence, Srx enzymatic activity can still be inhibited even if the
Srx-Prx binding is not affected. Therefore, we decided to further test both the
molecules to select one with specific activity.
Earlier publications from our group reported the role of Srx in promoting cell
growth and colony formation in NSCLC cell lines [32, 70]. Therefore, we decided
to test the effect of these chemicals on cell growth in lung cancer cell lines. For
confirming the specificity of effect, we simultaneously tested NSCLC cell lines,
SCLC lines, and a lung normal immortalized cell line (i.e. BEAS2B cells). Both
the chemicals inhibited lung cancer cell growth. The effect was more selective
towards inhibition of NSCLC cell lines compared to SCLC or non-cancer lung cell
lines. ZINC64002748 showed more potent inhibition of cell growth compared to
ISO1. Similarly, on testing in colony formation, both small molecules inhibited the
anchorage-independent colony formation in A549 cells.
An ideal inhibitor should have a higher affinity for the target enzyme compared to
its physiological substrate. We tested Srx-Prx affinity using SPR as reported in
Chapter 3 of this dissertation. To compare the affinities, we carried out SPR
analysis for individual chemicals. Both the chemicals showed higher affinity (i.e.
lower KD) for Srx compared to the Srx affinity for Prx. The affinity of ISO1 was
higher for Srx compared to that of ZINC64002748.
113

Another report from our group indicates that the Srx-Prx axis promotes
phosphokinase signaling in lung cancer cells [32]. Therefore, we expected Srx
inhibitors to reduce phosphokinase signaling in a manner similar to that observed
in the Srx-knockdown cell lines. The A549 cells were serum starved for 16-18
hours in the presence of 20 µM chemical inhibitor followed by stimulation of
phosphokinase signaling with media containing 10% serum and 100 ng/mL EGF.
The phosphokinase signaling was studied using western blot analysis and
specific

antibody

against

phosphorylated

proteins.

On

comparison

of

phosphokinase signal (especially p-c-Jun, p-CREB and p-ATF) at individual timepoints, we observed significant reduction in phosphokinase signaling in the ISO1
treatment

group

compared

to

DMSO

(vehicle)

treated

control

group.

ZINC64002748 failed to inhibit phosphokinase signaling in the expected manner.
The results of all experiments discussed so far led us to conclude that ISO1 may
be a more specific inhibitor of Srx compared to ZINC64002748. Even though the
latter showed more potent effect in inhibition of cell growth and colony formation,
it may be partially mediated through a mechanism other than inhibition of Srx-Prx
interaction. Considering the effect of ISO1 in all tests, we decided to further study
its effect on cancer cells. On testing its effect on cell cycle, we found that ISO1
inhibits the progression of cells to S-phase by blocking the majority of cells in
G1/G2 phase (mainly G2 phase). On comparing this effect to Srx knockdown, we
found that this effect is similar to the one observed in Srx-knockdown cells [32].
Similar to Srx-knockdown cells, ISO1 also inhibited tumor cell migration in the
wound healing assay. Taken together, ISO1 is a promising molecule that can
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inhibit Srx. All the tests performed in this study have confirmed specificity of ISO1
mechanism. Further QSAR studies can help to identify a Srx inhibitor with better
efficacy and pharmacokinetic profile.

4.6 Summary
The Srx hydrophobic pocket is directly involved in Srx-Prx binding. The
hydrophobic pocket is a well-defined druggable target site for inhibition of Srx-Prx
interaction. Virtual screening led to a list of multiple molecules that have potential
to bind with Srx. Careful selection of filters led to minimization of the number of
molecules to be tested in vitro. Seven molecules were tested in vitro for their
ability to inhibit the reduction of over-oxidized Prx by Srx. Two molecules
(ZINC64002748 and ZINC142037) out of 7 successfully inhibited reduction of
over-oxidized Prx. Further in vitro testing confirmed that ZINC142037 can inhibit
Srx specifically. ZINC142037 was named inhibitor of sulfiredoxin oxidoreductase
1 (ISO1). In the future, more QSAR studies can help identify a molecule related
to ISO1 that has better efficacy of Srx inhibition and a better pharmacokinetic
profile. ISO1 and other molecules identified using QSAR can be further explored
for their efficacy as chemotherapeutic molecules in lung cancer.
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CHAPTER 5 OVERALL DISCUSSION
5.1 Summary of dissertation
Srx is an exclusive molecule that can reduce over-oxidized Prx. The Srx-Prx axis
plays a critical role in a variety of physiological as well as pathological conditions
involving redox signaling. Some information is available about the cross-talk of
the Srx-Prx axis in several signaling pathways, but the factors that affect these
are largely unknown. Prx has clearly been shown to play a protective role in
cardiovascular and neurological diseases. However, its role in cancer is still
controversial due to both tumor-suppressor and oncogenic roles played by Prxisoforms in different cancer types. More in-depth mechanistic studies in the future
will help to unravel interweaved behavior of Prx and will lead to development of
better therapeutic strategies for cancer prevention or treatment. Srx itself plays
an oncogenic role in multiple types of cancer, including cancers of the skin,
colon, and lung. The biochemistry of Srx function has been studied in great
detail. However, the role of Srx in carcinogenesis needs a deeper understanding,
which can be fulfilled by future research. Considering the oncogenic roles of Srx,
it will be worth exploring Srx inhibitors as a molecule of choice for
chemoprevention and/or chemotherapy.
The majority of Srx functions are mediated through Srx-Prx interaction. Previous
publications from our research group have demonstrated the role of Srx-Prx
interaction in tumor promotion and metastasis. Based on existing information
available about the Srx-Prx interaction, we designed a general hypothesis that
Srx plays a critical role in lung carcinogenesis, and targeting the Srx-Prx axis or
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Srx alone may facilitate future development of targeted therapeutics for
prevention and treatment of lung cancer.
To test this hypothesis, we first demonstrated that Srx enhances urethaneinduced lung carcinogenesis (Specific Aim 1). Urethane is a well-known lung
carcinogen in mice [138]. Urethane is metabolized to vinyl carbamate epoxide,
which later causes the majority of urethane toxicity [143]. Humans are mainly
exposed to urethane from alcoholic beverages and cigarette smoke. Alcohol
increases the expression of CYP2E1 [145], which along with esterase are two
enzymes that play a main role in metabolism of urethane [146]. CYP2E1
converts urethane to vinyl carbamate epoxide, whereas esterase converts it to
ethanol [146]. Considering the stoichiometry of reaction, the presence of alcohol
has potential to slow down the metabolism of urethane by esterase. Hence, the
metabolism of urethane to vinyl carbamate epoxide becomes the predominant
mechanism of metabolism partially due to increased CYP2E1 expression and
partially due to reduced rate of metabolism by esterase. Many individuals
consume alcohol and smoke cigarettes at the same time [147]. Hence, the risk of
urethane toxicity and urethane-induced lung cancer may be higher in these
individuals. Human lungs have lower expression of urethane metabolizing
enzymes (i.e. CYP2E1) and esterase [148, 149], which multiplies the risk of
stoichiometric inhibition of esterase in human lungs. Hence, the risk of urethane
conversion to carcinogenic metabolite increases under regular exposure
conditions where lungs are simultaneously exposed to alcohol and cigarette
smoke.
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To study the role of Srx in lung carcinogenesis, we used the urethane model to
mimic lung cancer development in humans. Srx knockout mice were established
on an FVB background. Srx knockout mice were completely normal under
standard laboratory conditions. We demonstrated that depletion of Srx rendered
mice resistant to the urethane-induced lung cancer as Srx null mice showed
reduced tumor multiplicity as well as tumor diameter compared to wild type mice.
In mechanistic studies, we found that depletion of Srx led to reduction in cell
proliferation and increased the rate of intra-tumoral apoptosis. Reduced cell
proliferation and increased intra-tumoral apoptosis may contribute to tumorresistant phenotype of Srx knockout mice. Our findings of the tumor-resistant
phenotype of Srx knockout mice may reflect a long-term accumulative effect of
urethane exposure. Our findings suggest that Srx is one of the critical
components that contribute to mouse lung tumorigenesis in vivo. Targeting Srx
may thus be used as a novel strategy for lung cancer prevention and/or
treatment in the future.
Molecular interaction of individual proteins can regulate a variety of cell signaling
processes leading to their role in physiological homeostasis as well as
pathological conditions. We used computation methods of homology modeling
and protein-protein docking to study the characteristics of Srx-Prx interaction. A
great amount of biochemical data related to Srx-Prx interaction is already
available. We utilized both experimental and computational prediction data to
make a hypothesis that the C-terminal arm of typical 2-Cys Prxs may cause
steric hindrance for the Srx access to Prx. The experimental proofs of
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demonstrated that the C-terminal arm of Prx is not essential for Srx-Prx binding
(Specific Aim 2). Experimental evidence from existing literature suggests the
similarity in interaction of Srx with all four typical 2-Cys Prxs. However, by virtue
of being different proteins of same subfamily, they also have minor differences in
their characteristics. Our computational prediction indicated that those minor
differences in interaction could be due to different orientation of the C-terminal
arm in individual Prxs. To confirm our prediction on steric hindrance and role of
Prx C-terminal arm in Srx-Prx interaction, we carried out deletion mutation and
tested our hypothesis.
Due to similarities in typical 2-Cys Prx and accepted conventions in the field, we
decided to first study the effect of the C-terminal arm of Prx1 on its interaction
with Srx. Research in this field clearly establishes that differences in biochemistry
of Srx interaction with individual typical 2-Cys Prxs are small and it can be safely
assumed to be quite close to interaction characteristics of any other typical 2-Cys
Prx. The major differences among the four typical 2-Cys Prxs comes from their
subcellular localization rather than their molecular characteristics [30]. The Prx Cterminal arm contains 26 amino acids. Out of those, the initial four are critical for
Prx antioxidant function. However, the last 22 amino acids do not affect Prx
antioxidant function. Hence, we deleted the last 22 amino acids of the Prx1 Cterminal and studied the effect on Srx-Prx interaction.
The effect of deletion mutation was studied on both the steady-state Srx-Prx
interaction as well as kinetics of the Srx-Prx interaction. IP experiments indicated
that deletion mutation enhances the steady-state Srx-Prx interaction. However, it
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was not clear whether the effect on steady state interaction was due to changes
in rate of association or rate of dissociation or both. The SPR results indicated a
more than 1,000-fold increase in the association rate constant (ka) after deletion
of the C-terminal arm. Higher ka is a direct indicator of faster rate of association.
Hence, C-terminal arm deletion leads to approximately 1000-fold faster rate of
association than Prx1wildtype. The deletion mutation resulted in a slight change in
dissociation rate constant (kd). The ratio of kd/ka is equal to the equilibrium
dissociation rate constant (KD) in SPR. The reciprocal of KD is an indicator of
affinity of interaction. Hence, lower KD indicates better affinity of the Srx-Prx
interaction. The deletion mutation reduces the value of KD by more than 1000fold. Hence, Prx1 C-terminal arm deletion results in more than 1000- fold
increase in affinity of the Srx-Prx1 interaction.
To further confirm the applicability of these results to other typical 2-Cys Prxs, the
effect of the same deletion mutation was studied in Prx4. Considering differences
in C-terminal arm orientation (as predicted from homology modeling), we
expected that the extent of steric hindrance may be different than what we saw in
Prx1. This prediction was confirmed by SPR analysis of Srx interaction with
Prx4wildtype and Prx4mutant. The deletion mutation in Prx4 resulted in roughly 100fold increase in ka with minimal effect on kd. Again, the equilibrium dissociation
constant (KD) for the Srx-Prx4mutant interaction was calculated to be approximately
100 times lower than the KD for the Srx-Prx4wildtype interaction. Hence, the
deletion of the C-terminal arm of Prx affects the rate of the Srx-Prx association
and these results can be extrapolated to other typical 2-Cys Prxs. However, the
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extent of the effect may be different in different typical 2-Cys Prxs. This data
confirms that the C-terminal arm of Prx is present at the Srx-Prx interface and it
can cause some steric hindrance for Srx access to Prxs. The crystal structure of
Prx show slight conformational change in oxidized state. Srx access to Prx
further promotes a conformation change so that Srx can fit in Prx binding site.
Taken together, these results give us some insight about molecular
characteristics of the Srx-Prx interaction. Hence, this information about the SrxPrx interaction interface can help in successful designing of targeting strategies
to inhibit the Srx-Prx interaction.
Our experimental data along with existing literature helped us to identify the SrxPrx interaction interface. This interface could be targeted either by targeting the
amino acids in Srx chain that are present at interface, or amino acids in Prx chain
that are present at interface or dual binders that can bind both amino acids in Srx
interface as well as amino acids in Prx interface. Srx has three different sites that
can be targeted for inhibition of its enzymatic activity. Those sites include (1)
hydrophobic pocket; (2) the ATP and Mg2+ cofactor binding site; and (3) Cys99
and neighboring amino acids [54, 55, 163]. Considering the factors determining
specificity, we defined a complex 3-dimensional target site that included all
important amino acid components of hydrophobic pocket (Pro52, Leu82, Phe96,
Val118, Val127 and Tyr128) along with Cys99. Proximity of these amino acids to each
other made me believe that it would be a druggable target site. However,
druggability of a protein intramolecular target site can be affected by multiple
biochemical and structural factors. Therefore, I decided to confirm it with existing
121

druggable pocket prediction tools, i.e. MetaPocket 2.0 and ConCavity. The
druggability of the pocket defined in this study was confirmed by both in silico
prediction methods. Based on existing literature and earlier experiments, we
defined a pocket in the Prx dimer as a target site. However, the Prx binding
pocket druggability could not be confirmed using all methods. Considering the
narrower Prx pocket and inability to confirm its druggability by prediction method,
the chances of false positive in virtual screening was predicted to be high. Virtual
screening is not a 100% accurate method and human judgment must be used to
improve the chances of success. Both false positive as well as false –ve are high
in virtual screening if human judgment is not used. Due to minimal funding
available for this study, we decided to confine ourselves to virtual screening
against the Srx pocket and use Prx interface only for guidance for inhibition of
interaction. The virtual screening using DOCK Blaster and iGEMDOCK helped us
in selection of 1,400 hits out of 8,836,468 molecules that were originally
screened against Srx. To minimize the number of false positives, we utilized
multiple filters related to pharmacokinetic and pharmacodynamic parameters.
These filters helped us in minimizing the number to 100 chemicals. However, due
to economic constraints and lack of funding we could test only 7 chemicals.
Two of these chemicals (i.e. ZINC64002748 and ISO1) showed acceptable
inhibition of Prx-SO3 reduction at 20 µM concentrations (Specific Aim 3). Hence,
ZINC64002748 and ISO1 were selected for further in vitro testing in cell culture.
We next tested the ability of these chemicals to inhibit Srx-Prx and Srx-PrxSO3
interaction using pull-down assay. Compared to ZINC64002748, ISO1 showed
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more significant inhibition of the Prx and Prx-SO3 pull-down along with Srx. As
mentioned earlier, the hydrophobic pocket of Srx is responsible for Srx-Prx
binding while Cys99 (an amino acid outside the hydrophobic pocket) is
responsible for enzymatic activity. Hence, Srx enzymatic activity can still be
inhibited even if Srx-Prx binding is not affected. Therefore, we decided to further
test both the molecules to select one with specific activity.
Earlier publications from our group reported the role of Srx in promoting cell
growth and colony formation in NSCLC cell lines [32, 70]. Therefore, we decided
to test the effect of these chemicals on cell growth in lung cancer cell lines. For
confirming the specificity of effect, we simultaneously tested NSCLC cell lines,
SCLC lines, and a lung normal immortalized cell line (BEAS2B cells). Both the
chemicals inhibited lung cancer cell growth. The effect was more selective
towards inhibition of NSCLC cell lines compared to SCLC or non-cancer lung cell
lines. ZINC64002748 showed more potent inhibition of cell growth compared to
ISO1. However, the effect of ISO1 was more selective towards NSCLC cell lines.
Similarly, on testing in colony formation, both small molecules inhibited
anchorage-independent colony formation in A549 cells.
An ideal inhibitor should have higher affinity for the target enzyme compared to
its physiological substrate. To compare the affinities, we carried out SPR
analyses for the individual chemicals. Both the chemicals showed higher affinity
(i.e. lower KD) for Srx compared to the Srx affinity for Prx. The affinity of ISO1
was higher for Srx compared to that of ZINC64002748. Another report from our
group indicates that the Srx-Prx axis promotes phosphokinase signaling in lung
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cancer cells [32]. Therefore, we expected a Srx inhibitor to reduce
phosphokinase signaling in a manner similar to that observed in Srx-knockdown
cell lines. On comparison of phosphokinase signal (especially p-c-Jun, p-CREB
and p-ATF) at individual time-points, we observed significant reduction in
phosphokinase signaling in the ISO1 treatment group compared to DMSO
(vehicle)-treated control group. ZINC64002748 failed to inhibit phosphokinase
signaling in the expected manner.
The results of all experiments discussed so far led us to a conclusion that ISO1
may be a more specific inhibitor of Srx compared to ZINC64002748. Further
testing of ISO1 demonstrated its ability to inhibit cell cycle progression. ISO1
reduced the ability of cells to progress to S-phase by slowing down G1 and G2
phases. Similar to Srx-knockdown cells, ISO1 also inhibited tumor cell migration
in a wound healing assay. Taken together; ISO1 is a promising molecule that can
inhibit Srx. All the tests performed in this study have confirmed specificity of ISO1
mechanism. However, further QSAR studies can help to identify a Srx inhibitor
with better efficacy. In the future, more QSAR studies can help to identify a
molecule related to ISO1 that has better efficacy of Srx inhibition and better
pharmacokinetic profile. ISO1 and other molecules identified using QSAR study
can be further explored for their efficacy as a chemotherapeutic molecule in lung
cancer.
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5.2 Conclusions and future directions
Srx plays a critical role in lung carcinogenesis. Hence, it can be explored as a
potential target for chemoprevention as well as chemotherapy. The majority of
Srx actions are mediated through its interaction with Prx, which is a class of thiolbased antioxidant proteins. Hence, understanding the molecular characteristics
of Srx-Prx interaction can help in designing better targeting strategies against the
Srx-Prx axis. Our study first demonstrated the oncogenic role of Srx in urethaneinduced lung carcinogenesis (Specific Aim 1). Next we demonstrated the effect
of Prx C-terminal arm on Srx-Prx interaction. This study demonstrated that the
Prx C-terminal arm is present at Srx-Prx interface and it can cause steric
hindrance for Srx access to Prx (Specific Aim 2). Finally, we used in silico
methods to screen chemical databases and selected a few potential hits that can
act as inhibitors of Srx. On testing these molecules in vitro, we identified ISO1 as
a specific inhibitor of Srx (Specific Aim 3). ISO1 showed in vitro inhibition of lung
cancer cell growth as well as colony formation. However, its in vivo efficacy
needs to be tested in the future.
In the future, our lab can utilize QSAR approaches to identify a molecule that has
better efficacy of Srx-inhibition with better pharmacokinetic profile. These
molecules can be tested for their in vivo efficacy in chemoprevention and/or
chemotherapy.
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APPENDIX 1
Abbreviations
AP-1

activator protein-1

ATP

adenosine triphosphate

CP

peroxidatic cysteine (N-terminal cysteine)

CR

resolving cysteine (C-terminal cysteine)

CSC

cigarette smoke condensate

Cys

cysteine

DMSO

dimethyl sulfoxide

EGF

epidermal growth factor

EMT

epithelial-mesenchymal transition

GLC

general ligand coupling chip with compact capacity

GLH

general ligand coupling chip with high capacity

Het

Heterozygous i.e. Srx (+/-)

H&E

hematoxylin and eosin

IP

immunoprecipitation

ISO1

inhibitor of sulfiredoxin oxidoreductase 1

KO

Knockout i.e. Srx (-/-)

Nrf2

Nuclear factor erythroid 2 [NF-E2]-related factor 2

PBS

phosphate buffer saline

PCR

polymerase chain reaction

Prx

peroxiredoxin

PTEN

phosphatase and tensin homolog

PTP1B

protein-tyrosine phosphatase 1B

QSAR

quantitative structure-activity relationship
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RIPA

radioimmunoprecipitation assay buffer

RNS

reactive nitrogen species

ROS

reactive oxygen species

RT-PCR

reverse transcription - polymerase chain reaction

SCLC

small cell lung cancer

SPR

surface plasmon resonance

Srx

sulfiredoxin

TGF-β1

transforming growth factor-β1

TPA

12-O-tetradecanoyl-phorbol-13-acetate

TRAIL

tumor necrosis factor–related apoptosis-inducing ligand

Trx

thioredoxin

TUNEL

terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling

Wt

wild type i.e. Srx (+/+)
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